SALICYLATES
HAZARDTEXT ®
Information to help in the initial response for evaluating chemical incidents
 -IDENTIFICATION
SYNONYMS
Acetaminosalol Aluminum aspirin Ammonium salicylate Antipyrine salicylate Aspirin Benorylate Bismuth subsalicylate Bialpirina Bromosalicylic acid acetate Calcium aminosalicylate Calcium carbaspirin Carbamoylphenoxyacetic acid Choline salicylate Cospirn Diethylamine salicylate Ethyl salicylate Fendosal Glycol salicylate Homomenthyl salicylate Lithium salicylate Magnesium salicylate Menthyl salicylate Methyl salicylate Octyl salicylate Phenazone salicylate Phenyl aminosalicylate Phenyl salicylate Potassium aminosalicylate Potassium salicylate Salicylamide Salicylic acid Salsalate Silver salicylate Sodium aminosalicylate Sodium salicylate Sodium thiosalicylate Thurfyl salicylate Triethanolamine salicylate Trolamine salicylate For further information regarding aminosalicylic acid see MESALAMINE AND RELATED AGENTS.
- CONSTITUENTS OF THE GROUP
Acetaminosalol Aluminum aspirin Ammonium salicylate Antipyrine salicylate Aspirin Benorylate Bismuth subsalicylate Bialpirina Bromosalicylic acid acetate Calcium aminosalicylate Calcium carbaspirin Carbamoylphenoxyacetic acid Choline salicylate Cospirn Diethylamine salicylate Ethyl salicylate Fendosal Glycol salicylate Homomenthyl salicylate Lithium salicylate Magnesium salicylate Menthyl salicylate Methyl salicylate Octyl salicylate Phenazone salicylate Phenyl aminosalicylate Phenyl salicylate Potassium aminosalicylate Potassium salicylate Salicylamide Salicylic acid Salsalate Silver salicylate Sodium aminosalicylate Sodium salicylate Sodium thiosalicylate Thurfyl salicylate Triethanolamine salicylate Trolamine salicylate
IDENTIFIERS
18917-89-0(Magnesium Salicylate) 119-36-8(Methyl Salicylate) 578-36-9(Potassium Salicylate) 69-72-7(Salicylic Acid)
USES/FORMS/SOURCES
Salicylates are used primarily as antipyretics, analgesic and anti-inflammatory agents. Low dose salicylates are used to inhibit platelet aggregation in ischemic heart disease and cerebrovascular disease. Bismuth subsalicylate is used to treat diarrhea and as prophylaxis for travellers diarrhea. Salicylate ointments are used for the anti-inflammatory effects in rheumatological conditions and for the keratolytic properties in dermal conditions such as ichthyosis and psoriasis. Oil of wintergreen is used as a flavoring for candy (Howrie et al, 1985). Salicylates are used in some teething ointments (Payntes & Alexander, 1979). In Asia, preparations containing menthyl salicylate are sold for a variety of indications, including muscle and joint aches, bruises, cuts, burns, infected wounds, insect bites, abdominal pain, headache, toothache, motion sickness, and colds (Chan, 2002; Chan et al, 1995; Chan, 1996).
Salicylates are available as tablets, capsules, powders, effervescent tablets and liquid preparations for ingestion. They are available as rectal suppositories as a chewing gum. Salicylates are also available as liniments, creams and lotions for topical application. Methyl salicylate is found in many plants. As of November 1997, the FDA requires an alcohol warning on all over-the-counter pain relievers, which includes aspirin, other salicylates, acetaminophen, ibuprofen, ketoprofen, and naproxen sodium, due to a potential drug interaction resulting in upper GI bleed or liver damage.
ASPIRIN: CHILDREN's aspirin contains 75 to 81 milligrams per tablet; ADULT aspirin contains 325 to 650 milligrams per tablet. COMBINATION PRODUCTS: Salicylate is often combined with antihistamines and decongestants, or caffeine in cold and allergy preparations (Sainsbury, 1991). Several products contain combinations of acetaminophen and salicylate (Todd et al, 1981; Beringer, 1984). SUSTAINED RELEASE preparations of aspirin contain aspirin released over a 12 hour or longer period of time. Prolonged absorption and persistently elevated salicylate levels may occur following overdose. ENTERIC-COATED FORMULATIONS: Designed to dissolve in the alkaline medium of the small intestine, these formulations may cause bezoars and prolonged drug absorption. BISMUTH SUBSALICYLATE is an over-the-counter preparation containing 130 milligram/15 milliliter to 236 milligram/15 milliliter of salicylate for the liquid formulation, 99 to 102 milligrams of salicylate per chewable tablet, and 99 milligrams of salicylate per caplet. It is used in the treatment of diarrhea and prophylaxis for travellers diarrhea (Prod Info Pepto-Bismol Original Liquid, Maximum Strength Liquid, Original and Cherry Tablets and Easy-to-Swallow Caplets, 2004; Anon, 1980; Sainsbury, 1991; Levy, 1993). TOPICAL USE HOMOMENTHYL SALICYLATE (HOMOSALATE) is a sunscreen agent found in many sunscreen products and contains 46% salicylic acid. Homosalate could be hydrolyzed in vivo to free salicylic acid and homomenthol. There are, however, no reported cases of salicylate intoxication resulting from ingestion or dermal application of sunscreens containing homomenthyl salicylate (Personal Communication, 1981). OCTYL SALICYLATE - Measurable salicylate levels and reports of symptomatology have occurred in children after ingesting Octyl Salicylate 5%, a topical sunscreen agent (Quail MT, 1994). TROLAMINE SALICYLATE cream (10 grams of cream contains 500 milligrams of salicylic acid) is used in the management of osteoarthritis (O'Brien, 1982). SALICYLATE in PETROLATUM - A topical 20% salicylate in petrolatum caused salicylism in a newborn with ichthyosis. Salicylate concentration on day 7 was 119 milligram/deciliter (therapeutic: 15 to 30 milligram/deciliter) (Yamamura et al, 2002). LINIMENTS - Various liniments contain salicylates which are absorbed percutaneously (range is 15% to 30% methyl salicylate). METHYL SALICYLATE (OIL OF WINTERGREEN): Commercial preparations are not less than 98% w/w. One milliliter of 98% methyl salicylate is equivalent to 1.4 grams ASA in salicylate potency and its action is the same as salicylates; or one teaspoonful of oil of wintergreen (5 milliliters) is equivalent to approximately 7000 milligram of salicylate or 21.7 adult aspirin tablets (Botma et al, 2001), which could result in serious toxicity in children less than 6 years with an average weight of less than 23 kg (Davis, 2007). It is absorbed through the skin and may be used undiluted or as part of a liniment or ointment (Gordon, 1968); the ointment has also been accidentally ingested by children (Botma et al, 2001). HERBAL/CHINESE MEDICINES: Asian products containing methyl salicylate include koong yick hung far oil, red flower oil, red oil Chinese, tiger oil, golden lion shield medicated oil, kwan loong oil, pak fah yeow, white flower oil, white flower embrocation, and axe brand universal oil (Davis, 2007; Tam et al, 1995; Chan et al, 1995; Chan, 1996; Baxter et al, 2001). CASE SERIES: In a retrospective study of 24 adults who had ingested white flower oil (n=18) or red flower oil (n=6), no subjects ingesting white flower oil developed symptoms, while 50% of the individuals ingesting red flower oil developed moderate to severe symptoms. Thirty-three percent of those cases required urine alkalinization. Red flower oil usually has a 50% to 60% methyl salicylate concentration, as compared to 40% methyl salicylate in white flower oil. Red flower oil may also contain turpentine oil, cinnamon leaf oil, and eucalyptus oil. All patients recovered except one who died of hospital-acquired pneumonia (Chan, 2002). The authors suggested packaging improvements to decrease or avoid the amount that can be easily ingested due to existing packaging. CASE REPORT: Salicylism was reported in an elderly patient with a history of dementia who ingested Red Oil Chinese which was found to contain methyl salicylate (the product had a concentration of 70% along with turpentine oil, palm olean, and cinnamon oil) (Baxter et al, 2001).
Non-aspirin salicylates (NAS) are used in many over-the-counter lotions, ointments, creams, liniments, and sunscreens because of their antipyretic, analgesic, and anti-inflammatory abilities (Quail MT, 1994). Systemic effects have been reported following pediatric ingestions.
OTHER SALT FORMS include sodium salicylate as 324 to 650 mg tablets or capsules 325 and 500 milligrams (86% salicylate), calcium carbaspirin as 352 milligram tablets (30% salicylate), magnesium salicylate as 600 milligram tablets (93% salicylate), choline salicylate as liquid 870 milligrams/5 milliliters (57% salicylate), salsalate as 500 mg capsule (106% salicylate), aluminum aspirin as 670 mg tablet (68% salicylate), and potassium salicylate (78% salicylate). Aluminum aspirin, magnesium salicylate, and salsalate are hydrolyzed to 2 molecules of salicylate. ALOXIPRIN is a polymeric condensation product of aluminum oxide and aspirin. 600 mg of aloxiprin is equivalent to 500 mg of ASA. PLANTS: Acacia (flower oil), Aspens, Birches, Calycanthus (leaves), Camellia (leaves), Chenopodium (leaves), Hyacinth, Marigold, Milkwort, Poplars, Spiraea, Teaberry, Tulips, Violets (Shelley, 1964). FOODS (Shelley, 1964): Almonds Apples Apricots Blackberries Cherries Currants Gooseberries Grapes Nectarines Oranges Peaches Plums Raspberries Birch beer Teaberry tea Wines
-CLINICAL EFFECTS
GENERAL CLINICAL EFFECTS
- USES: Salicylates are used primarily as an analgesic, antipyretic, anti-inflammatory, and antiplatelet agent. Found in many over-the-counter preparations in oral and topical forms. It may also be found in combination with other agents such as narcotics, barbiturates, and caffeine. Topical forms are often used as rubefacients. Also found in some essential oils in high concentrations such as oil of wintergreen.
- PHARMACOLOGY: Salicylates inhibit cyclooxygenase, thereby reducing the formation of prostaglandins, and cause platelet dysfunction.
- TOXICOLOGY: Salicylates stimulate the respiratory center in the brainstem, interfere with the Krebs cycle (limiting ATP production), uncouple oxidative phosphorylation (causing accumulation of pyruvic and lactic acid and heat production), and increase fatty acid metabolism (generating ketone bodies). The net result is a mixed respiratory alkalosis and metabolic acidosis.
- EPIDEMIOLOGY: Common poisoning which can result in significant morbidity and mortality.
MILD TO MODERATE TOXICITY: GI upset, tinnitus, tachypnea, and respiratory alkalosis. SEVERE TOXICITY: Metabolic acidosis, hyperpnea, diaphoresis, fever, altered mental status, seizures, coma, cerebral edema, pulmonary edema and death. Chronic overdoses present more insidiously and may be subtle, especially in the elderly, and may consist primarily of neurologic manifestations such as confusion, delirium, and agitation. Coagulopathy, hepatic injury, and dysrhythmias are rare complications of severe overdose. DELAYED TOXICITY: Onset of clinical toxicity and peak serum levels may be delayed in patients with ingestion of sustained release or enteric coated aspirin, or if pylorospasm or pharmacobezoar develop. Patients should be monitored until serial serum salicylate levels are declining and clinical symptoms have improved.
- Editor's Note: An ERG guide with information appropriate to this material does not exist.
-FIRST AID
FIRST AID AND PREHOSPITAL TREATMENT
ASPIRIN: Patients ingesting more than 150 mg/kg or 6.5 g, whichever is less, of aspirin equivalent doses should be referred to a health care facility; activated charcoal can be administered in the prehospital setting if readily available in patients with normal mental status. For children under 6 years of age, ingestions of greater than a lick or a taste of oil of wintergreen (98% methyl salicylate) should be referred to a health care facility. For patients older than 6 years of age, ingestions of 4 mL or greater of oil of wintergreen (98% methyl salicylate) should be referred to a health care facility. Delayed onset of clinical toxicity and peak serum levels may develop after ingestion of enteric coated or sustained release salicylate or if pylorospasm or pharmacobezoar develop.
Prehospital administration of activated charcoal for acute toxic salicylate ingestions can be considered if it is immediately available and no contraindications are present. Transportation to a hospital should not be delayed in order to administer the activated charcoal. PREHOSPITAL ACTIVATED CHARCOAL ADMINISTRATION Consider prehospital administration of activated charcoal as an aqueous slurry in patients with a potentially toxic ingestion who are awake and able to protect their airway. Activated charcoal is most effective when administered within one hour of ingestion. Administration in the prehospital setting has the potential to significantly decrease the time from toxin ingestion to activated charcoal administration, although it has not been shown to affect outcome (Alaspaa et al, 2005; Thakore & Murphy, 2002; Spiller & Rogers, 2002). In patients who are at risk for the abrupt onset of seizures or mental status depression, activated charcoal should not be administered in the prehospital setting, due to the risk of aspiration in the event of spontaneous emesis. The addition of flavoring agents (cola drinks, chocolate milk, cherry syrup) to activated charcoal improves the palatability for children and may facilitate successful administration (Guenther Skokan et al, 2001; Dagnone et al, 2002).
CHARCOAL DOSE Use a minimum of 240 milliliters of water per 30 grams charcoal (FDA, 1985). Optimum dose not established; usual dose is 25 to 100 grams in adults and adolescents; 25 to 50 grams in children aged 1 to 12 years (or 0.5 to 1 gram/kilogram body weight) ; and 0.5 to 1 gram/kilogram in infants up to 1 year old (Chyka et al, 2005). Routine use of a cathartic with activated charcoal is NOT recommended as there is no evidence that cathartics reduce drug absorption and cathartics are known to cause adverse effects such as nausea, vomiting, abdominal cramps, electrolyte imbalances and occasionally hypotension (None Listed, 2004).
ADVERSE EFFECTS/CONTRAINDICATIONS Complications: emesis, aspiration (Chyka et al, 2005). Aspiration may be complicated by acute respiratory failure, ARDS, bronchiolitis obliterans or chronic lung disease (Golej et al, 2001; Graff et al, 2002; Pollack et al, 1981; Harris & Filandrinos, 1993; Elliot et al, 1989; Rau et al, 1988; Golej et al, 2001; Graff et al, 2002). Refer to the ACTIVATED CHARCOAL/TREATMENT management for further information. Contraindications: unprotected airway (increases risk/severity of aspiration) , nonfunctioning gastrointestinal tract, uncontrolled vomiting, and ingestion of most hydrocarbons (Chyka et al, 2005).
-RANGE OF TOXICITY
MINIMUM LETHAL EXPOSURE
CHRONIC A 52-year-old man ingested an estimated 96 grams of aspirin over nine days and died despite emergency treatment (Kearney, 1989). An 18-month-old boy died after receiving one baby aspirin every 4 to 6 hours for two days (Snodgrass et al, 1981). A 64-year-old woman died after inadvertently receiving 7,100 milligrams of enteric coated aspirin daily for 10 days (Shkrum et al, 1989).
ACUTE OIL OF WINTERGREEN Five milliliters of oil of wintergreen is equivalent to approximately 7000 milligrams of salicylate (Botma et al, 2001). Fatalities have been reported in children following methyl salicylate exposure with the lowest reported dose being 4 mL in 2 children (17 months and a 2-year-old) (Davis, 2007) A 2-year-old boy ingested approximately 7.5 milliliters of oil of wintergreen and died. He died before receiving treatment (MacCready, 1943). A 21-year-old man died after ingesting 6 mL of oil of wintergreen (Davis, 2007). A 44-year-old man died after accidentally ingesting 30 milliliters of oil of wintergreen (Cauthen & Hester, 1989).
PEPTO-BISMOL
MAXIMUM TOLERATED EXPOSURE
ACUTE The acute ingestion of less than 150 mg/kg or 6.5 g of aspirin equivalent, whichever is less, is not expected to cause significant toxicity. For oil of wintergreen (98% methylsalicylate), greater than a lick or taste by children under 6 years of age or greater than 4 mL by patients 6 years of age and older may cause toxicity and requires referral to an emergency department for evaluation (Chyka et al, 2007). Acutely, less than 150 mg/kg of ASA will result in mild to moderate GI symptoms and mild irritability. Moderate intoxication can occur after ingesting 150 to 300 mg/kg and serious effects are likely after ingesting greater than 300 mg/kg (Temple, 1981).
OIL OF WINTERGREEN Oil of wintergreen, a flavoring agent, is approximately 98% methyl salicylate and has caused severe toxicity and death in both adults and children. PEDIATRIC: A 2-year-old girl survived after ingesting 15 to 30 milliliters of oil of wintergreen. She was treated with fluid therapy only (MacCready, 1943). CASE REPORTS: There have been several reports in the literature of young children (2 to 3.5 years old) surviving an estimated oil of wintergreen ingestions of 30 to 60 mL, but these children underwent aggressive therapy including exchange transfusion or peritoneal dialysis (Davis, 2007).
TOPICAL SALICYLIC CASE REPORT: A 2-month-old infant, with crusta lactea, developed salicylate toxicity after inadvertently being treated with an occlusive dressing containing 50% salicylic acid applied for 3 days. Laboratory evaluation showed metabolic acidosis (pH 7.33, base excess -13 mM/L), a normal calculated anion gap (3.5 mM/L) and hyperchloremia (chloride 129 mmol/L). A salicylate level of 42.5 mg/dL was obtained 48 hours after the last topical application. The infant recovered completely following forced diuresis and urinary alkalinization. In this case, the diagnosis of salicylate toxicity was initially difficult due to a falsely elevated chloride level which was caused by laboratory interference in the presence of an elevated salicylate level. Its suggested that some ion-selective electrodes may be more susceptible due to a loss of selectivity of the chloride electrode following chronic use and possible competition between salicylate and chloride ions to bind to albumin (Vazquez Martinez et al, 2015). CASE REPORT: A newborn with ichthyosis (characterized by excessive scales on the skin) was treated with salicylic vaseline from day 1 through the 9th day of life and developed salicylate toxicity. A topical 20% salicylate in petrolatum was applied twice daily over most of the body. Salicylate concentration on day 7 was 119 mg/dL (therapeutic: 15 to 30 mg/dL). Following supportive care, including peritoneal dialysis and mechanical ventilation, the infant was discharged with no neurologic deficit except for moderate abnormal auditory brainstem response on day 57 (Yamamura et al, 2002).
The most serious salicylate poisoning results from too frequent or excessive administration of the drug for therapeutic purposes (Done & Temple, 1971; Done, 1978). Chronic salicylism is associated with greater morbidity in adults (Anderson et al, 1976) and children (Gaudreault et al, 1982). All suspected chronic poisonings should be evaluated by a physician. Chronic ingestion of greater than 100 mg/kg/day over 2 or more days is thought to be associated with toxicity (Temple, 1981). Doses of 150 mg/kg and 95 mg/kg used for 2 weeks have been associated with toxicity in children (Evereson & Krenzelok, 1986) (Quint & Allman, 1984). CASE REPORT (INFANT): A 3-month-old infant developed vomiting, tachycardia, tachypnea, metabolic acidosis, and CNS depression following chronic administration of a product containing bismuth subsalicylate, up to 15 mL/day (equivalent to 86 mg/kg of aspirin) for 3.5 weeks. Following supportive care, the patient gradually recovered and was discharged without sequelae (Lewis et al, 2006).
- Carcinogenicity Ratings for CAS18917-89-0 :
ACGIH (American Conference of Governmental Industrial Hygienists, 2010): Not Listed EPA (U.S. Environmental Protection Agency, 2011): Not Listed IARC (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004): Not Listed NIOSH (National Institute for Occupational Safety and Health, 2007): Not Listed MAK (DFG, 2002): Not Listed NTP (U.S. Department of Health and Human Services, Public Health Service, National Toxicology Project ): Not Listed
- Carcinogenicity Ratings for CAS119-36-8 :
ACGIH (American Conference of Governmental Industrial Hygienists, 2010): Not Listed EPA (U.S. Environmental Protection Agency, 2011): Not Listed IARC (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004): Not Listed NIOSH (National Institute for Occupational Safety and Health, 2007): Not Listed MAK (DFG, 2002): Not Listed NTP (U.S. Department of Health and Human Services, Public Health Service, National Toxicology Project ): Not Listed
- Carcinogenicity Ratings for CAS578-36-9 :
ACGIH (American Conference of Governmental Industrial Hygienists, 2010): Not Listed EPA (U.S. Environmental Protection Agency, 2011): Not Listed IARC (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004): Not Listed NIOSH (National Institute for Occupational Safety and Health, 2007): Not Listed MAK (DFG, 2002): Not Listed NTP (U.S. Department of Health and Human Services, Public Health Service, National Toxicology Project ): Not Listed
- Carcinogenicity Ratings for CAS69-72-7 :
ACGIH (American Conference of Governmental Industrial Hygienists, 2010): Not Listed EPA (U.S. Environmental Protection Agency, 2011): Not Listed IARC (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004): Not Listed NIOSH (National Institute for Occupational Safety and Health, 2007): Not Listed MAK (DFG, 2002): Not Listed NTP (U.S. Department of Health and Human Services, Public Health Service, National Toxicology Project ): Not Listed
TOXICITY AND RISK ASSESSMENT VALUES
- EPA Risk Assessment Values for CAS18917-89-0 (U.S. Environmental Protection Agency, 2011):
- EPA Risk Assessment Values for CAS119-36-8 (U.S. Environmental Protection Agency, 2011):
- EPA Risk Assessment Values for CAS578-36-9 (U.S. Environmental Protection Agency, 2011):
- EPA Risk Assessment Values for CAS69-72-7 (U.S. Environmental Protection Agency, 2011):
SALICYLIC ACID, ACETATE LD50- (INTRAVENOUS)DOG: LD50- (INTRAPERITONEAL)MOUSE: LD50- (ORAL)MOUSE: LD50- (SUBCUTANEOUS)MOUSE: LD50- (INTRAPERITONEAL)RAT: LD50- (ORAL)RAT: LD50- (RECTAL)RAT:
-STANDARDS AND LABELS
WORKPLACE STANDARDS
- ACGIH TLV Values for CAS18917-89-0 (American Conference of Governmental Industrial Hygienists, 2010):
- ACGIH TLV Values for CAS119-36-8 (American Conference of Governmental Industrial Hygienists, 2010):
- ACGIH TLV Values for CAS578-36-9 (American Conference of Governmental Industrial Hygienists, 2010):
- ACGIH TLV Values for CAS69-72-7 (American Conference of Governmental Industrial Hygienists, 2010):
- AIHA WEEL Values for CAS18917-89-0 (AIHA, 2006):
- AIHA WEEL Values for CAS119-36-8 (AIHA, 2006):
- AIHA WEEL Values for CAS578-36-9 (AIHA, 2006):
- AIHA WEEL Values for CAS69-72-7 (AIHA, 2006):
- NIOSH REL and IDLH Values for CAS18917-89-0 (National Institute for Occupational Safety and Health, 2007):
- NIOSH REL and IDLH Values for CAS119-36-8 (National Institute for Occupational Safety and Health, 2007):
- NIOSH REL and IDLH Values for CAS578-36-9 (National Institute for Occupational Safety and Health, 2007):
- NIOSH REL and IDLH Values for CAS69-72-7 (National Institute for Occupational Safety and Health, 2007):
- OSHA PEL Values for CAS18917-89-0 (U.S. Occupational Safety, and Health Administration (OSHA), 2010):
- OSHA PEL Values for CAS119-36-8 (U.S. Occupational Safety, and Health Administration (OSHA), 2010):
- OSHA PEL Values for CAS578-36-9 (U.S. Occupational Safety, and Health Administration (OSHA), 2010):
- OSHA PEL Values for CAS69-72-7 (U.S. Occupational Safety, and Health Administration (OSHA), 2010):
- OSHA List of Highly Hazardous Chemicals, Toxics, and Reactives for CAS18917-89-0 (U.S. Occupational Safety and Health Administration, 2010):
- OSHA List of Highly Hazardous Chemicals, Toxics, and Reactives for CAS119-36-8 (U.S. Occupational Safety and Health Administration, 2010):
- OSHA List of Highly Hazardous Chemicals, Toxics, and Reactives for CAS578-36-9 (U.S. Occupational Safety and Health Administration, 2010):
- OSHA List of Highly Hazardous Chemicals, Toxics, and Reactives for CAS69-72-7 (U.S. Occupational Safety and Health Administration, 2010):
ENVIRONMENTAL STANDARDS
- EPA CERCLA, Hazardous Substances and Reportable Quantities for CAS18917-89-0 (U.S. Environmental Protection Agency, 2010):
- EPA CERCLA, Hazardous Substances and Reportable Quantities for CAS119-36-8 (U.S. Environmental Protection Agency, 2010):
- EPA CERCLA, Hazardous Substances and Reportable Quantities for CAS578-36-9 (U.S. Environmental Protection Agency, 2010):
- EPA CERCLA, Hazardous Substances and Reportable Quantities for CAS69-72-7 (U.S. Environmental Protection Agency, 2010):
- EPA CERCLA, Hazardous Substances and Reportable Quantities, Radionuclides for CAS18917-89-0 (U.S. Environmental Protection Agency, 2010):
- EPA CERCLA, Hazardous Substances and Reportable Quantities, Radionuclides for CAS119-36-8 (U.S. Environmental Protection Agency, 2010):
- EPA CERCLA, Hazardous Substances and Reportable Quantities, Radionuclides for CAS578-36-9 (U.S. Environmental Protection Agency, 2010):
- EPA CERCLA, Hazardous Substances and Reportable Quantities, Radionuclides for CAS69-72-7 (U.S. Environmental Protection Agency, 2010):
- EPA RCRA Hazardous Waste Number for CAS18917-89-0 (U.S. Environmental Protection Agency, 2010b):
- EPA RCRA Hazardous Waste Number for CAS119-36-8 (U.S. Environmental Protection Agency, 2010b):
- EPA RCRA Hazardous Waste Number for CAS578-36-9 (U.S. Environmental Protection Agency, 2010b):
- EPA RCRA Hazardous Waste Number for CAS69-72-7 (U.S. Environmental Protection Agency, 2010b):
- EPA SARA Title III, Extremely Hazardous Substance List for CAS18917-89-0 (U.S. Environmental Protection Agency, 2010):
- EPA SARA Title III, Extremely Hazardous Substance List for CAS119-36-8 (U.S. Environmental Protection Agency, 2010):
- EPA SARA Title III, Extremely Hazardous Substance List for CAS578-36-9 (U.S. Environmental Protection Agency, 2010):
- EPA SARA Title III, Extremely Hazardous Substance List for CAS69-72-7 (U.S. Environmental Protection Agency, 2010):
- EPA SARA Title III, Community Right-to-Know for CAS18917-89-0 (40 CFR 372.65, 2006; 40 CFR 372.28, 2006):
- EPA SARA Title III, Community Right-to-Know for CAS119-36-8 (40 CFR 372.65, 2006; 40 CFR 372.28, 2006):
- EPA SARA Title III, Community Right-to-Know for CAS578-36-9 (40 CFR 372.65, 2006; 40 CFR 372.28, 2006):
- EPA SARA Title III, Community Right-to-Know for CAS69-72-7 (40 CFR 372.65, 2006; 40 CFR 372.28, 2006):
- DOT List of Marine Pollutants for CAS18917-89-0 (49 CFR 172.101 - App. B, 2005):
- DOT List of Marine Pollutants for CAS119-36-8 (49 CFR 172.101 - App. B, 2005):
- DOT List of Marine Pollutants for CAS578-36-9 (49 CFR 172.101 - App. B, 2005):
- DOT List of Marine Pollutants for CAS69-72-7 (49 CFR 172.101 - App. B, 2005):
- EPA TSCA Inventory for CAS18917-89-0 (EPA, 2005):
- EPA TSCA Inventory for CAS119-36-8 (EPA, 2005):
- EPA TSCA Inventory for CAS578-36-9 (EPA, 2005):
- EPA TSCA Inventory for CAS69-72-7 (EPA, 2005):
LABELS
- NFPA Hazard Ratings for CAS18917-89-0 (NFPA, 2002):
- NFPA Hazard Ratings for CAS119-36-8 (NFPA, 2002):
- NFPA Hazard Ratings for CAS578-36-9 (NFPA, 2002):
- NFPA Hazard Ratings for CAS69-72-7 (NFPA, 2002):
-PERSONAL PROTECTION
SUMMARY
- Editor's Note: An ERG guide with information appropriate to this material does not exist.
PROTECTIVE CLOTHING
- CHEMICAL PROTECTIVE CLOTHING. Search results for CAS 18917-89-0.
- CHEMICAL PROTECTIVE CLOTHING. Search results for CAS 119-36-8.
- CHEMICAL PROTECTIVE CLOTHING. Search results for CAS 578-36-9.
- CHEMICAL PROTECTIVE CLOTHING. Search results for CAS 69-72-7.
-PHYSICAL HAZARDS
FIRE HAZARD
- FLAMMABILITY CLASSIFICATION
- NFPA Flammability Rating for CAS18917-89-0 (NFPA, 2002):
- NFPA Flammability Rating for CAS119-36-8 (NFPA, 2002):
- NFPA Flammability Rating for CAS578-36-9 (NFPA, 2002):
- NFPA Flammability Rating for CAS69-72-7 (NFPA, 2002):
- FIRE CONTROL/EXTINGUISHING AGENTS
- Editor's Note: An ERG guide with information appropriate to this material does not exist.
- NFPA Extinguishing Methods for CAS18917-89-0 (NFPA, 2002):
- NFPA Extinguishing Methods for CAS119-36-8 (NFPA, 2002):
- NFPA Extinguishing Methods for CAS578-36-9 (NFPA, 2002):
- NFPA Extinguishing Methods for CAS69-72-7 (NFPA, 2002):
EVACUATION PROCEDURES
- Editor's Note: An ERG guide with information appropriate to this material does not exist.
- AIHA ERPG Values for CAS18917-89-0 (AIHA, 2006):
- AIHA ERPG Values for CAS119-36-8 (AIHA, 2006):
- AIHA ERPG Values for CAS578-36-9 (AIHA, 2006):
- AIHA ERPG Values for CAS69-72-7 (AIHA, 2006):
- DOE TEEL Values for CAS18917-89-0 (U.S. Department of Energy, Office of Emergency Management, 2010):
- DOE TEEL Values for CAS119-36-8 (U.S. Department of Energy, Office of Emergency Management, 2010):
Listed as Methyl salicylate TEEL-0 (units = ppm): 0.1 TEEL-1 (units = ppm): 0.3 TEEL-2 (units = ppm): 2 TEEL-3 (units = ppm): 12.5 Definitions: TEEL-0: The threshold concentration below which most people will experience no adverse health effects. TEEL-1: The airborne concentration (expressed as ppm [parts per million] or mg/m(3) [milligrams per cubic meter]) of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic, nonsensory effects. However, these effects are not disabling and are transient and reversible upon cessation of exposure. TEEL-2: The airborne concentration (expressed as ppm or mg/m(3)) of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting, adverse health effects or an impaired ability to escape. TEEL-3: The airborne concentration (expressed as ppm or mg/m(3)) of a substance above which it is predicted that the general population, including susceptible individuals, could experience life-threatening adverse health effects or death.
- DOE TEEL Values for CAS578-36-9 (U.S. Department of Energy, Office of Emergency Management, 2010):
- DOE TEEL Values for CAS69-72-7 (U.S. Department of Energy, Office of Emergency Management, 2010):
Listed as Salicylic acid TEEL-0 (units = mg/m3): 0.3 TEEL-1 (units = mg/m3): 0.75 TEEL-2 (units = mg/m3): 6 TEEL-3 (units = mg/m3): 400 Definitions: TEEL-0: The threshold concentration below which most people will experience no adverse health effects. TEEL-1: The airborne concentration (expressed as ppm [parts per million] or mg/m(3) [milligrams per cubic meter]) of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic, nonsensory effects. However, these effects are not disabling and are transient and reversible upon cessation of exposure. TEEL-2: The airborne concentration (expressed as ppm or mg/m(3)) of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting, adverse health effects or an impaired ability to escape. TEEL-3: The airborne concentration (expressed as ppm or mg/m(3)) of a substance above which it is predicted that the general population, including susceptible individuals, could experience life-threatening adverse health effects or death.
- AEGL Values for CAS18917-89-0 (National Research Council, 2010; National Research Council, 2009; National Research Council, 2008; National Research Council, 2007; NRC, 2001; NRC, 2002; NRC, 2003; NRC, 2004; NRC, 2004; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; United States Environmental Protection Agency Office of Pollution Prevention and Toxics, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; 62 FR 58840, 1997; 65 FR 14186, 2000; 65 FR 39264, 2000; 65 FR 77866, 2000; 66 FR 21940, 2001; 67 FR 7164, 2002; 68 FR 42710, 2003; 69 FR 54144, 2004):
- AEGL Values for CAS119-36-8 (National Research Council, 2010; National Research Council, 2009; National Research Council, 2008; National Research Council, 2007; NRC, 2001; NRC, 2002; NRC, 2003; NRC, 2004; NRC, 2004; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; United States Environmental Protection Agency Office of Pollution Prevention and Toxics, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; 62 FR 58840, 1997; 65 FR 14186, 2000; 65 FR 39264, 2000; 65 FR 77866, 2000; 66 FR 21940, 2001; 67 FR 7164, 2002; 68 FR 42710, 2003; 69 FR 54144, 2004):
- AEGL Values for CAS578-36-9 (National Research Council, 2010; National Research Council, 2009; National Research Council, 2008; National Research Council, 2007; NRC, 2001; NRC, 2002; NRC, 2003; NRC, 2004; NRC, 2004; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; United States Environmental Protection Agency Office of Pollution Prevention and Toxics, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; 62 FR 58840, 1997; 65 FR 14186, 2000; 65 FR 39264, 2000; 65 FR 77866, 2000; 66 FR 21940, 2001; 67 FR 7164, 2002; 68 FR 42710, 2003; 69 FR 54144, 2004):
- AEGL Values for CAS69-72-7 (National Research Council, 2010; National Research Council, 2009; National Research Council, 2008; National Research Council, 2007; NRC, 2001; NRC, 2002; NRC, 2003; NRC, 2004; NRC, 2004; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; United States Environmental Protection Agency Office of Pollution Prevention and Toxics, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2009; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2008; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2007; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2005; National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances, 2006; 62 FR 58840, 1997; 65 FR 14186, 2000; 65 FR 39264, 2000; 65 FR 77866, 2000; 66 FR 21940, 2001; 67 FR 7164, 2002; 68 FR 42710, 2003; 69 FR 54144, 2004):
- NIOSH IDLH Values for CAS18917-89-0 (National Institute for Occupational Safety and Health, 2007):
- NIOSH IDLH Values for CAS119-36-8 (National Institute for Occupational Safety and Health, 2007):
- NIOSH IDLH Values for CAS578-36-9 (National Institute for Occupational Safety and Health, 2007):
- NIOSH IDLH Values for CAS69-72-7 (National Institute for Occupational Safety and Health, 2007):
CONTAINMENT/WASTE TREATMENT OPTIONS
-PHYSICAL/CHEMICAL PROPERTIES
MOLECULAR WEIGHT
- ASPIRIN: 180.16 (Prod Info DURLAZA(TM) oral extended release capsules, 2015; Prod Info AGGRENOX(R) oral capsules, 2009)
- BISMUTH SUBSALICYLATE: 362.11 (Prod Info HELIDAC(R) Therapy oral chewable tablets, tablets, capsules, 2007)
- CHOLINE MAGNESIUM TRISALICYLATE: 539.8 (Prod Info choline magnesium trisalicylate oral tablets, 1999)
DESCRIPTION/PHYSICAL STATE
- ASPIRIN: Odorless, white, crystalline or powdery substance that is highly lipid soluble, slightly soluble in water (Prod Info AGGRENOX(R) oral capsules, 2009), and soluble in ethanol (Prod Info DURLAZA(TM) oral extended release capsules, 2015).
- BISMUTH SUBSALICYLATE: Fine, white, odorless, and tasteless powder that is nonhygroscopic (Prod Info HELIDAC(R) Therapy oral chewable tablets, tablets, capsules, 2007).
- CHOLINE MAGNESIUM TRISALICYLATE: Freely soluble in water (Prod Info choline magnesium trisalicylate oral tablets, 1999).
-REFERENCES
GENERAL BIBLIOGRAPHY- 40 CFR 372.28: Environmental Protection Agency - Toxic Chemical Release Reporting, Community Right-To-Know, Lower thresholds for chemicals of special concern. National Archives and Records Administration (NARA) and the Government Printing Office (GPO). Washington, DC. Final rules current as of Apr 3, 2006.
- 40 CFR 372.65: Environmental Protection Agency - Toxic Chemical Release Reporting, Community Right-To-Know, Chemicals and Chemical Categories to which this part applies. National Archives and Records Association (NARA) and the Government Printing Office (GPO), Washington, DC. Final rules current as of Apr 3, 2006.
- 49 CFR 172.101 - App. B: Department of Transportation - Table of Hazardous Materials, Appendix B: List of Marine Pollutants. National Archives and Records Administration (NARA) and the Government Printing Office (GPO), Washington, DC. Final rules current as of Aug 29, 2005.
- 62 FR 58840: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 1997.
- 65 FR 14186: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2000.
- 65 FR 39264: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2000.
- 65 FR 77866: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2000.
- 66 FR 21940: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2001.
- 67 FR 7164: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2002.
- 68 FR 42710: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2003.
- 69 FR 54144: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2004.
- AIHA: 2006 Emergency Response Planning Guidelines and Workplace Environmental Exposure Level Guides Handbook, American Industrial Hygiene Association, Fairfax, VA, 2006.
- AMA Department of DrugsAMA Department of Drugs: AMA Evaluations Subscription, American Medical Association, Chicago, IL, 1992.
- Abdel-Magid EHM & Ahmed FREA: Salicylate intoxication in an infant with ichthyosis transmitted through skin ointment - a case report. Pediatrics 1994; 94:939-940.
- Abrams KL: Hypocalcemia associated with administration of sodium bicarbonate for salicylate intoxication in a cat. J Am Vet Med Assoc 1987; 191:235-236.
- Adelman HM, Wallach PM, & Flannery MT: Inability to interpret toxic salicylate levels in patients taking aspirin and diflunisal. J Rheumatol 1991; 18:522-523.
- Ahlfors CE, Shwer Ml, & Ford KB: Bilirubin-albumin binding in neonatal salicylate intoxication. Dev Pharmacol Ther 1982; 4:47-60.
- Alaspaa AO, Kuisma MJ, Hoppu K, et al: Out-of-hospital administration of activated charcoal by emergency medical services. Ann Emerg Med 2005; 45:207-12.
- Alberich RS, Jammoul A, & Masana L: Henoch-Schonlein purpura associated with acetylsalicylic acid (letter). Ann Intern Med 1997; 126:665.
- Alvan G, Bergman U, & Gustafsson LL: High unbound fraction of salicylate in plasma during intoxication (letter). Br J Clin Pharmac 1981; 11:625-626.
- Am Acad Neurol: Practice parameter: The management of concussion in sports (summary statement). Report of the Quality Standards Subcommittee. Neurology 1997; 48:581-585.
- American Conference of Governmental Industrial Hygienists : ACGIH 2010 Threshold Limit Values (TLVs(R)) for Chemical Substances and Physical Agents and Biological Exposure Indices (BEIs(R)), American Conference of Governmental Industrial Hygienists, Cincinnati, OH, 2010.
- Andersen R & Refstad S: Adult respiratory distress syndrome precipitated by massive salicylate poisoning. Intens Care Med 1978; 4:211-213.
- Anderson JAR & Ead RD: Percutaneous salicylate poisoning. Clin Exp Derm 1979; 4:349-351.
- Anderson RJ, Potts DE, & Gabow PA: Unrecognized adult salicylate intoxication. Ann Intern Med 1976; 85:745-748.
- Anderson RJ: Asterixis as a manifestation of salicylate toxicity. Ann Intern Med 1981; 95:188-189.
- Anon: Salicylate in pepto-bismol. Med Lett Drugs Ther 1980; 22:63.
- Ansell-Edmont: SpecWare Chemical Application and Recommendation Guide. Ansell-Edmont. Coshocton, OH. 2001. Available from URL: http://www.ansellpro.com/specware. As accessed 10/31/2001.
- Arena PA, Dugowson C, & Saudek CD: Salicylate-induced hypoglycemia and ketoacidosis in a nondiabetic adult. Arch Intern Med 1978; 138:1153-1154.
- Aspinall JB & Goel KM: Salicylate poisoning in dermatological therapy (letter). Br Med J 1978; 1373.
- Asselin WM & Caughlin JD: A rapid and simple color test for detection of salicylate in whole hemolyzed blood. J Anal Toxicol 1990; 14:254-255.
- Austin TR: Anaesthesia in salicylate overdosage (letter). Br J Anaesth 1970; 42:80-81.
- Bailey RB & Jones SR: Chronic salicylate intoxication: a common cause of morbidity in the elderly. J Am Geriatr Soc 1989; 37:556-561.
- Bannwarth B, Netter P, & Pourel J: Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs in the cerebrospinal fluid. Biomed Pharmacother 1989; 43:121-126.
- Barone JA, Raia JJ, & Huang YC: Evaluation of the effects of multiple-dose activated charcoal on the absorption of orally administered salicylate in a simulated toxic ingestion model. Ann Emerg Med 1988; 17:34-37.
- Barrett MJ: Association of Reye's syndrome with use of Pepto-Bismol(R) (bismuth subsalicylate). Ped Infect Dis 1986; 5:610-611.
- Bata Shoe Company: Industrial Footwear Catalog, Bata Shoe Company, Belcamp, MD, 1995.
- Battison C, Andrews PJ, Graham C, et al: Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med 2005; 33(1):196-202.
- Baxter A, Mrvos R, & Krenzelok EP: Beware of salicylism and herbal medicines (abstract). J Toxicol - Clin Toxicol 2001; 39:549.
- Baxter AJ, Mrvos R, & Krenzelok EP: Salicylism and herbal medicine (letter). Am J Emerg Med 2003; 21:448-449.
- Berg KJ: Acute acetylsalicylic acid poisoning: treatment with forced alkaline diuresis and diuretics. Europ J Clin Pharmacol 1977; 12:111-116.
- Beringer RO: Salicylate intoxication in the elderly due to benorlate. Br Med J 1984; 288:1344-1345.
- Berk WA & Andersen JC: Salicylate-associated asystole: report of two cases. Am J Med 1989; 86:505-506.
- Berkovitch M, Uziel Y, Greenberg R, et al: False-high blood salicylate levels in neonates with hyperbilirubinemia. Ther Drug Monit 2000; 22(6):757-761.
- Bernard TJ, Goldenberg NA, Armstrong-Wells J, et al: Treatment of childhood arterial ischemic stroke. Ann Neurol 2008; 63(6):679-696.
- Bernstein JM & Weiss AD: Further observations on salicylate ototoxicity. J Laryngol Otol 1967; 81:915-925.
- Best Manufacturing: ChemRest Chemical Resistance Guide. Best Manufacturing. Menlo, GA. 2002. Available from URL: http://www.chemrest.com. As accessed 10/8/2002.
- Best Manufacturing: Degradation and Permeation Data. Best Manufacturing. Menlo, GA. 2004. Available from URL: http://www.chemrest.com/DomesticPrep2/. As accessed 04/09/2004.
- Bismuth C, Frejaville JP, & Pebay-Peyroula F: Rhabdomyolyse diffuse mortelle an cours d'une intoxication par salicycles et nifuroxazide. Nouv Presse Med 1972; 1:397-399.
- Blanca M, Perez E, & Garcia JJ: Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy 1989; 62:295-298.
- Boss Manufacturing Company: Work Gloves, Boss Manufacturing Company, Kewanee, IL, 1998.
- Botma M, Colquhoun-Flannery W, & Leighton S: Laryngeal oedema caused by accidental ingestion of oil of wintergreen. Internat J Pediat Otorhinolaryngol 2001; 58:229-232.
- Bove KE, Bhathena D, & Wyatt RJ: Diffuse metanephric adenoma after in utero aspirin intoxication. Arch Pathol Lab Med 1979; 103:187-190.
- Brem J, Pereli EM, & Gopalan SK: Salicylism, hyperventilation, and the central nervous system. J Pediatr 1973; 83:264-266.
- Briggs GG, Freeman RK, & Yaffe SJBriggs GG, Freeman RK, & Yaffe SJ: Drugs in Pregnancy and Lactation, 5th. Williams & Wilkins, Baltimore, MD, 1998.
- Broder JN: The ferric chloride screening test (letter). Ann Emerg Med 1987; 16:1188.
- Brookings CH & Ramsey JD: Salicylate removal by charcoal haemoprefusion in experimental intoxication in dogs: an assessment of efficacy and safety. Arch Toxicol 1975; 34:243-252.
- Brophy GM, Bell R, Claassen J, et al: Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17(1):3-23.
- Brown GL & Wilson WP: Salicylate intoxication and the CNS: with special reference to EEG findings. Dis Nerv Sys 1971; 135-140.
- Brubacher JR & Hoffman RS: Salicylism from topical salicylates (abstract). J Tox Clin Tox 1995; 33:546-547.
- Buchanan N & Rabinowitz L: Infantile salicylism. A reappraisal. J Pediatr 1974; 84:391-395.
- Buck ML, Grebe TA, & Bond GR: Toxic reaction to salicylate in a newborn infant: similarities to neonatal sepsis. J Pediatr 1993; 122:955-958.
- Bullock R, Chesnut RM, & Clifton G: Guidelines for the management of severe head injury. Eur J Emerg Med 1996; 2:109-127.
- Burgess JL, Kirk M, Borron SW, et al: Emergency department hazardous materials protocol for contaminated patients. Ann Emerg Med 1999; 34(2):205-212.
- Burton BT, Bayer MJ, & Barron L: Comparison of activated charcoal and gastric lavage in the prevention of aspirin absorption. J Emerg Med 1984; 1:411-416.
- Buselmeier TJ, Lynch RE, & Davin TD: Severe salicylate intoxication in small children: a practical approach to therapy. Minn Med 1977; 60:472-477.
- Cabooter M, Elewaut A, & Barbier F: Salicylate-induced pancreatitis (letter). Gastroenterology 1981; 80:214-215.
- Camasara JG, Lluch M, & Serra-Baldrich E: Allergic contact dermatitis from 3-(aminomethyl)-pyridyl salicylate. Contact Dermatitis 1989; 20:347-351.
- Candy JM, Morrison C, & Paton RD: Salicylate toxicity masquerading as malignant hyperthermia. Pediatric Anaesthesia 1998; 8:421-423.
- Caravati EM, Knight HH, & Linscott MS: Esophageal laceration and charcoal mediastinum complicating gastric lavage. J Emerg Med 2001; 20:273-276.
- Caravati EM: Phytonadione (Vitamin K1). In: Dart RC, ed. Medical Toxicology, Lippincott Williams & Wilkins, Philadelphia, PA, 2004.
- Case MES, Short CD, & Poklis A: Intoxication by aspirin and alcohol in a child. Am J Forensic Med Pathol 1983; 4:149-151.
- Cauthen WL & Hester WH: Accidental ingestion of oil of wintergreen. J Fam Pract 1989; 29:680-681.
- Cazals Y: Auditory sensori-neural alterations induced by salicylate. Progress in Neurobiol 2000; 62:583-631.
- Cersosimo RJ & Matthews SJ: Hepatotoxicity associated with choline magnesium trisalicylate: case report and review of salicylate-induced hepatotoxicity. Drug Intell Clin Pharm 1987; 21:621-625.
- Chamberlain JM, Altieri MA, & Futterman C: A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Ped Emerg Care 1997; 13:92-94.
- Chan TY: Ingestion of medicated oils by adults: the risk of severe salicylate poisoning is related to the packaging of these products. Hum Exp Toxicol 2002; 21(4):171-174.
- Chan TYK, Leung C, & Ng DYF: Inadequate warnings and misleading information in OTC package inserts for medicated oils containing methyl salicylate (letter). Ann Pharmacother 1995; 29:1301-1302.
- Chan TYK: Medicated oils and severe salicylate poisoning: quantifying the risk based on methyl salicylate content and bottle size. Vet Human Toxicol 1996; 38:133-134.
- Chapman BJ & Proudfoot AT: Adult salicylate poisoning: deaths and outcome in patients with high plasma salicylate concentrations. Quart J Med 1989; 72:699-707.
- Charette JD, Zager S, & Storrow AB: Trinder's bedside test for qualitative determination of salicylate ingestions. Am J Emerg Med 1998; 16:546.
- ChemFab Corporation: Chemical Permeation Guide Challenge Protective Clothing Fabrics, ChemFab Corporation, Merrimack, NH, 1993.
- Chin RF , Neville BG , Peckham C , et al: Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol 2008; 7(8):696-703.
- Cholette JM, Mamikonian L, Alfieris GM, et al: Aspirin resistance following pediatric cardiac surgery. Thromb Res 2010; 126(3):200-206.
- Choonara IA & Rane A: Therapeutic drug monitoring of anticonvulsants state of the art. Clin Pharmacokinet 1990; 18:318-328.
- Christensen LA & Schmidt EB: Perforated peptic ulcer-a complication in acute salicylate intoxication. Acta Med Scand 1987; 222:191-192.
- Chyka PA , Erdman AR , Christianson G , et al: Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007; 45(2):95-131.
- Chyka PA, Seger D, Krenzelok EP, et al: Position paper: Single-dose activated charcoal. Clin Toxicol (Phila) 2005; 43(2):61-87.
- Clark JH & Wilson WG: A 16-day-old breast-fed infant with metabolic acidosis caused by salicylate. Clin Pediatr 1981; 20:53-54.
- Comasec Safety, Inc.: Chemical Resistance to Permeation Chart. Comasec Safety, Inc.. Enfield, CT. 2003. Available from URL: http://www.comasec.com/webcomasec/english/catalogue/mtabgb.html. As accessed 4/28/2003.
- Comasec Safety, Inc.: Product Literature, Comasec Safety, Inc., Enfield, CT, 2003a.
- Consensus Conference: Diagnosis and treatment of Reye's syndrome. JAMA 1981; 246:2441-2444.
- Coppack SW & Higgins: Algorithm for modified alkaline diuresis in salicylate poisoning (letter). Br Med J 1984; 289:1452.
- Corby DG: Aspirin in pregnancy: maternal and fetal effects. Pediatrics 1978; 62(suppl):930-937.
- Craig GP: Systems of Measurement and Common Equivalents. In: Clinical Calculations Made Easy: Solving Problems Using Dimensional Analysis, 3rd ed. Lippincott Williams & Wilkins, Philadelphia, PA, 2005.
- Cross SE, Anderson C, & Thompson MJ: Is there tissue penetration after application of topical salicylate formulations?. Lancet 1997; 350:636.
- DFG: List of MAK and BAT Values 2002, Report No. 38, Deutsche Forschungsgemeinschaft, Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, Wiley-VCH, Weinheim, Federal Republic of Germany, 2002.
- Dadgar D, Climax J, & Lambe R: High-performance liquid chromatographic determination of certain salicylates and their major metabolites in plasma following topical administration of a liniment to healthy subjects. J Chromatogr 1985; 342:315-321.
- Dagnone D, Matsui D, & Rieder MJ: Assessment of the palatability of vehicles for activated charcoal in pediatric volunteers. Pediatr Emerg Care 2002; 18:19-21.
- Danel V, Henry JA, & Glucksman E: Activated charcoal, emesis, and gastric lavage in aspirin overdose. Br Med J 1988; 296:1507.
- Daniels SR, Greenberg RS, & Ibrahim MA: Scientific uncertainties in the studies of salicylate use and Reye's syndrome. JAMA 1983; 249:1311-1361.
- Dargan PI, Jones AL, & Salimi GP: Hemofiltration - a potential new treatment for salicylate poisoning (abstract). J Toxicol - Clin Toxicol 2001; 39:483.
- Davies MG, Briffa DV, & Greaves MW: Systemic toxicity from topically applied salicylic acid. Br Med J 1979; 1:661.
- Davis JE: Are one or two dangerous? Methyl salicylate exposure in toddlers. J Emerg Med 2007; 32(1):63-69.
- Dawling S, Chand S, & Braithwaite RA: In vitro and in vivo evaluation of two preparations of activated charcoal as adsorbents of aspirin. Human Toxicol 1983; 2:211-216.
- Dellinger TM & Livingston HM: Aspirin burn of the oral cavity. Ann Pharmacother 1998; 32:1107.
- Done AK & Otterness LJ: Exchange transfusion in the treatment of oil of wintergreen (methyl salicylate) poisoning. Pediatrics 1956; 18:80-85.
- Done AK & Temple AR: Treatment of salicylate poisoning. Modern Treat 1971; 8:528-551.
- Done AK: Aspirin overdose: incidence, diagnosis and management. Pediatrics 1978; 62(suppl):890-897.
- Done AK: Salicylate intoxication: Significance of measurements of salicylates in blood in cases of acute ingestion. Pediatrics 1960; 26:800-807.
- Douidar SM, Hale TW, & Trevino D: The effect of multiple dose activated charcoal (MDAC) on the elimination of intravenous (IV) sodium salicylate (NaSA) in rabbits (abstract). Vet Hum Toxicol 1992; 34:362.
- Dove DJ & Jones T: Delayed coma associated with salicylate intoxication. J Pediatr 1982; 100:493-496.
- DuPont: DuPont Suit Smart: Interactive Tool for the Selection of Protective Apparel. DuPont. Wilmington, DE. 2002. Available from URL: http://personalprotection.dupont.com/protectiveapparel/suitsmart/smartsuit2/na_english.asp. As accessed 10/31/2002.
- DuPont: Permeation Guide for DuPont Tychem Protective Fabrics. DuPont. Wilmington, DE. 2003. Available from URL: http://personalprotection.dupont.com/en/pdf/tyvektychem/pgcomplete20030128.pdf. As accessed 4/26/2004.
- DuPont: Permeation Test Results. DuPont. Wilmington, DE. 2002a. Available from URL: http://www.tyvekprotectiveapprl.com/databases/default.htm. As accessed 7/31/2002.
- Duffens KR, Smilkstein MJ, & Bessen HA: Falsely elevated salicylate levels due to diflunisal overdose. J Emerg Med 1987; 5:499-503.
- Dugandzic RM, Tierney MG, & Dickinson GE: Evaluation of the validity of the Done Nomogram in the management of acute salicylate intoxication. Ann Emerg Med 1989; 18:1186-1190.
- Dwyer CM, McCloskey RH, & Kerr REI: Poisoning from topical salicylic acid (Letter). Postgrad Med J 1994a; 70:146.
- Dwyer Cm, McCloskey RH, & Kerr REI: Poisoning from topical salicylic acid (letter). Postgrad Med J 1994; 70:146.
- EPA: Search results for Toxic Substances Control Act (TSCA) Inventory Chemicals. US Environmental Protection Agency, Substance Registry System, U.S. EPA's Office of Pollution Prevention and Toxics. Washington, DC. 2005. Available from URL: http://www.epa.gov/srs/.
- Eder H: Chronic toxicity studies on phenacetin, N-acetyl-p-aminophenol (NAPA) and acetylsalicylic acid in cats. Acta Pharmacol Toxicol 1964; 21:197-204.
- Eisen TF, Grbcich PA, & Lacouture PG: The adsorption of salicylates by a milk chocolate-charcoal mixture. Ann Emerg Med 1991; 20:143-146.
- Elko C & Von Derau K: Salicylate undetected for 8 hours after enteric-coated aspirin overdose. J Toxicol - Clin Toxicol 2001; 39:482-483.
- Elliot CG, Colby TV, & Kelly TM: Charcoal lung. Bronchiolitis obliterans after aspiration of activated charcoal. Chest 1989; 96:672-674.
- English M, Marsh V, & Amukoye E: Chronic salicylate poisoning and severe malaria. Lancet 1996; 347:1736-1737.
- Etteldorf JN, Dobbins WT, & Summitt RL: Intermittent peritoneal dialysis using 5 per cent albumin in the treatment of salicylate intoxication in children. J Pediatr 1961; 58:226-236.
- Everson GW & Krenzelok EP: Chronic salicylism in a patient with juvenile rheumatoid arthritis. Clin Pharm 1986; 5:334-341.
- FDA: Food & Drug Administration, Final Rule. Fed Reg 1990; 55:27776-27784, Government Printing Office, Washington, DC, 1990.
- FDA: Over-the-counter drug products containing analgesic/antipyretic active ingredients for internal use; required alcohol warning. FDA: Federal Register 1998; 63:56789-56802.
- FDA: Poison treatment drug product for over-the-counter human use; tentative final monograph. FDA: Fed Register 1985; 50:2244-2262.
- Falcini F, Cimaz R, Calabri GB, et al: Kawasaki's disease in northern Italy: a multicenter retrospective study of 250 patients. Clin Exp Rheumatol 2002; 20(3):421-426.
- Fantozzi R, Martinelli F, & Masini E: Use of haemoperfusion with uncoated charcoal in the management of acute intoxications with barbiturate and salicylate. Substan Alcohol Act Mis 1981; 2:55-62.
- Feldman S, Chen SL, & Pickering LK: Salicylate absorption from a bismuth subsalicylate preparation. Clin Phrmacol Ther 1981; 29:788-792.
- Feldman Z, Kanter MJ, & Robertson CS: Effect of head elevation on intracranial pressure, cerebral perfusion pressure, and cerebral blood flow in head-injured patients. J Neurosurg 1992; 76:207-211.
- Ferguson RK & Boutros AR: Death following self-poisoning with aspirin. JAMA 1970; 213:1186-1187.
- Filippone GA, Fish SS, & Lacouture PG: Reversible absorption (desorption) of aspirin from activated charcoal. Arch Intern Med 1987; 147:1390-1392.
- Findlay JWA, DeAngelis RL, & Kearney MF: Analgesic drugs in breast milk and plasma. Clin Pharmacol Ther 1981; 29:625-633.
- Fiscina S: Death associated with aspirin overdose. Mil Med 1986; 151:499.
- Fisher CJ Jr, Albertson TE, & Foulke GE: Salicylate-induced pulmonary edema: clinical characteristics in children. Am J Emerg Med 1985; 3:33-37.
- Fishler JJ: Effect of aspirin on the gastric mucosa (dogs). Sm Animal Clin 1963; 3:39-40.
- Flomenbaum NE, Goldfrank LR, & Hoffman RS: Salicylates. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds. Goldfrank's Toxicologic Emergencies. 8th ed., McGraw-Hill Companies, Inc. McGraw-Hill Companies, Inc, NY, NY, 2006, pp -.
- Ford M, Tomaszewski C, & Kerns W: Bedside ferric chloride urine test to rule out salicylate intoxication (abstract). Vet Hum Toxicol 1994; 36:103.
- Fox GN: Hypocalcemia complicating bicarbonate therapy for salicylate poisoning. West J Med 1984; 141:108-109.
- Gabow PA, Anderson RJ, & Potts DE: Acid-base disturbances in the salicylate-intoxicated adult. Arch Intern Med 1978; 138:1481-1484.
- Galea P & Goel KM: Salicylate poisoning in dermatological treatment. Arch Dis Child 1990; 65:335.
- Garrettson LK & Procknal JA and Levy G: Fetal acquisition and neonatal elimination of a large amount of salicylate. Study of a neonate whose mother regularly took therapeutic doses of aspirin during pregnancy. Clin Pharmacol Ther 1975; 17:98-103.
- Garrettson LK, Procknal JA, & Levy G: Fetal acquisition and neonatal elimination of a large amount of salicylate. Study of a neonate whose mother regularly took therapeutic doses of aspirin during pregnancy. Clin Pharmacol Ther 1975; 17:98-103.
- Gaudreault P, Temple AR, & Lovejoy FH: The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison. Pediatrics 1982; 70:566-569.
- Gilman AG, Goodman LS, & Gilman A: The Pharmacological Basis of Therapeutics, 6th ed, MacMillan Co, New York, NY, 1980.
- Gittelman DK: Chronic salicylate intoxication. South Med J 1993; 86:683-685.
- Glezen WP: Aspirin and Reye's syndrome. (Comments). Am J Dis Child 1982; 136:971-972.
- Golej J, Boigner H, Burda G, et al: Severe respiratory failure following charcoal application in a toddler. Resuscitation 2001; 49:315-318.
- Gordon IJ, Bowler CS, & Coakley J: Algorithm for modified alkaline diuresis in salicylate poisoning. Br Med J 1984; 289:1039-1040.
- Gordon RR: Poisoning by oil of wintergreen (letter). Br Med J 1968; 769.
- Grabe DW, Manley HJ, & Kim JS: Respiratory distress caused by salicylism confirmed by lung biopsy. Clin Drug Invest 1999; 17:79-81.
- Graff GR, Stark J, & Berkenbosch JW: Chronic lung disease after activated charcoal aspiration. Pediatrics 2002; 109:959-961.
- Guardian Manufacturing Group: Guardian Gloves Test Results. Guardian Manufacturing Group. Willard, OH. 2001. Available from URL: http://www.guardian-mfg.com/guardianmfg.html. As accessed 12/11/2001.
- Guenther Skokan E, Junkins EP, & Corneli HM: Taste test: children rate flavoring agents used with activated charcoal. Arch Pediatr Adolesc Med 2001; 155:683-686.
- Hadley C, Wolowich W, & Kelley M: The oral absorption of methyl salicylate from topical formulations (abstract). J Tox Clin Tox 1997; 35:545-546.
- Halla JT & Hardin JG: Salicylate ototoxicity in patients with rheumatoid arthritis: a controlled study. Ann Rheum Dis 1988; 47:134-137.
- Halla JT, Atchison SL, & Hardin JG: Symptomatic salicylate ototoxicity: a useful indicator of serum salicylate concentration?. Ann Rheum Dis 1991; 50:682-684.
- Halla JT, Fallahi S, & Hardin JG: Acute and chronic salicylate intoxication in a patient with gastric outlet obstruction. Arthritis Rheum 1981; 24:1205-1207.
- Hamdan JA, Manasra K, & Ahmed M: Salicylate-induced hepatitis in rheumatic fever. Am J Dis Child 1985; 139:453-455.
- Hansen JR, McCray PB, & Bale JF Jr: Reye syndrome associated with aspirin therapy for systemic lupus erythematosus. Pediatrics 1985; 76:202-205.
- Hantsch C, Seger D, & Meredith T: Intra-alveolar hemorrhage in fatal salicylate toxicity (abstract). J Tox Clin Tox 1998; 36:445-446.
- Harris CR & Filandrinos D: Accidental administration of activated charcoal into the lung: aspiration by proxy. Ann Emerg Med 1993; 22:1470-1473.
- Harris FC: Pyloric stenosis: hold-up of enteric coated aspirin tablets. Brit J Surg 1973; 60:979-981.
- Hearney EG, Fuhrer J, & Mariuz P: Photo quiz. Clin Infect Dis 1996; 23:37-159.
- Heffner JE & Sahn SA: Salicylate-induced pulmonary edema. Ann Intern med 1981; 95:405-409.
- Hegenbarth MA & American Academy of Pediatrics Committee on Drugs: Preparing for pediatric emergencies: drugs to consider. Pediatrics 2008; 121(2):433-443.
- Heng MCY: Local necrosis and interstitial nephritis due to topical methyl salicylate and menthol. Cutis 1987; 39:442-444.
- Herres J, Ryan D, & Salzman M: Delayed salicylate toxicity with undetectable initial levels after large-dose aspirin ingestion. Am J Emerg Med 2009; 27(9):1173e1-1173e3.
- Herrgesell JD: Aspirin poisoning in the cat. J Am Vet Med Assoc 1967; 151:452-455.
- Higgins RM, Connolly JO, & Hendry BM: Alkalinization and hemodialysis in severe salicylate poisoning: comparison of elimination techniques in the same patient. Clin Nephrol 1998; 50:178-183.
- Hill JB: Experimental salicylate poisoning: observations on the effects of altering blood pH on tissue and plasma salicylate concentrations. Pediatrics 1971; 47:658-665.
- Hillman RJ & Prescott LF: Treatment of salicylate poisoning with repeated oral charcoal. Br Med J 1985; 291:1492.
- Hoffman RJ, Nelson LS, & Hoffman RS: Use of ferric chloride to identify salicylate-containing poisons. J Toxicol Clin Toxicol 2002; 40(5):547-549.
- Hormaechea E, Carlson RW, & Rogoue H: Hypovolemia, pulmonary edema and protein changesin severe salicylate poisoning. Am J Med 1979; 66:1046-1050.
- Howrie DL, Moriarty R, & Breit R: Candy flavoring as a source of salicylate poisoning. Pediatrics 1985; 75:869-871.
- Hrnicek G, Skelton J, & Miller WC: Pulmonary edema and salicylate intoxication. JAMA 1974; 230:866-867.
- Hsieh KS, Weng KP, Lin CC, et al: Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics 2004; 114(6):e689-e693.
- Hurwitz ES, Barrett MJ, & Bregman D: Public health service study on Reye's syndrome and medications: report of the pilot phase. N Engl J Med 1985; 313:849-856.
- Hvidberg EF & Dam M: Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976; 1:161.
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: 1,3-Butadiene, Ethylene Oxide and Vinyl Halides (Vinyl Fluoride, Vinyl Chloride and Vinyl Bromide), 97, International Agency for Research on Cancer, Lyon, France, 2008.
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol, 88, International Agency for Research on Cancer, Lyon, France, 2006.
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Household Use of Solid Fuels and High-temperature Frying, 95, International Agency for Research on Cancer, Lyon, France, 2010a.
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines, 89, International Agency for Research on Cancer, Lyon, France, 2007.
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Non-heterocyclic Polycyclic Aromatic Hydrocarbons and Some Related Exposures, 92, International Agency for Research on Cancer, Lyon, France, 2010.
- IARC: List of all agents, mixtures and exposures evaluated to date - IARC Monographs: Overall Evaluations of Carcinogenicity to Humans, Volumes 1-88, 1972-PRESENT. World Health Organization, International Agency for Research on Cancer. Lyon, FranceAvailable from URL: http://monographs.iarc.fr/monoeval/crthall.html. As accessed Oct 07, 2004.
- ILC Dover, Inc.: Ready 1 The Chemturion Limited Use Chemical Protective Suit, ILC Dover, Inc., Frederica, DE, 1998.
- International Agency for Research on Cancer (IARC): IARC monographs on the evaluation of carcinogenic risks to humans: list of classifications, volumes 1-116. International Agency for Research on Cancer (IARC). Lyon, France. 2016. Available from URL: http://monographs.iarc.fr/ENG/Classification/latest_classif.php. As accessed 2016-08-24.
- International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. World Health Organization. Geneva, Switzerland. 2015. Available from URL: http://monographs.iarc.fr/ENG/Classification/. As accessed 2015-08-06.
- Israels SJ & Michelson AD: Antiplatelet therapy in children. Thromb Res 2006; 118(1):75-83.
- Jacobsen D, Wiik-Larsen E, & Bredesen JE: Haemodialysis or haemoperfusion in severe salicylate poisoning. Hum Toxicol 1988; 7:161-163.
- James JA, Kimbell L, & Read WT: Experimental salicylate intoxication. I. Comparison of exchange transfusion, intermittent peritoneal lavage, and hemodialysis as means for removing salicylate. Pediatrics 1962; 442.
- Janssen T, Boege P, & Oestreicher E: Tinnitus and 2f1-f2 distortion product otoacoustic emissions following salicylate overdose. J Accoust Soc Am 2000; 107:1790-1792.
- Kahn A & Blum D: Methyl alcohol poisoning in an 8-month-old boy: an unusual route of intoxication. J Pediatr 1979; 94:841-843.
- Kanada SA, Kolling WM, & Hindin BI: Aspirin Hepatotoxicity. Am J Hosp Pharm 1978; 35:330-336.
- Kaplan EH, Kennedy J, & Davis J: Effects of salicylate and other benzoates on oxidative enzymes of the tricarboxylic acid cycle in rat tissue homogenates. Arch Biochem Biophys 1954; 51:47-61.
- Kappler, Inc.: Suit Smart. Kappler, Inc.. Guntersville, AL. 2001. Available from URL: http://www.kappler.com/suitsmart/smartsuit2/na_english.asp?select=1. As accessed 7/10/2001.
- Karlowicz MG & White LE: Severe intracranial hemorrhage in a term neonate associated with maternal acetylsalicylic acid ingestion. Clin Pediatr 1993; 740-743.
- Kauffman RE: Reye's syndrome and salicylate use, by Karen M. Starko, MD, et al, Pediatrics, 1980; 66:859-864; and National patterns of aspirin use and Reye syndrome reporting, United States, 1980 to 1985, by Janet B. Arrowsmith et al, Pediatrics, 1987; 79:858-863 (Commentary). Pediatrics 1998; 102(Suppl):259-262.
- Kearney TE: Salicylate poisoning: recognition and management. Emerg Med Services 1989; 18:39-43.
- Kennedy J & Telford J: Altered mental status in salicylate poisoning: reversal with IV glucose (abstract). J Tox Clin Tox 1998; 36:445.
- Kent K, Ganetsky M, Cohen J, et al: Non-fatal ventricular dysrhythmias associated with severe salicylate toxicity. Clin Toxicol (Phila) 2008; 46(4):297-299.
- Kimberly-Clark, Inc.: Chemical Test Results. Kimberly-Clark, Inc.. Atlanta, GA. 2002. Available from URL: http://www.kc-safety.com/tech_cres.html. As accessed 10/4/2002.
- Kirkpatrick PJ: On guidelines for the management of the severe head injury (editorial). J Neurol Neurosurg Psychiatr 1997; 62:109-111.
- Kirschenbaum LA, Mathews SC, & Sitar DS: Whole-bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified-release pharmaceuticals. Clin Pharmacol Ther 1989; 46:264-271.
- Kirshenbaum LA, Mathews SC, & Sitar DS: Does multiple-dose charcoal therapy enhance salicylate excretion?. Arch Intern Med 1990; 150:1281-1283.
- Kirshenbaum LA, Mathews SC, & Sitar DS: Whole-bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified-release pharmaceuticals. Clin Pharmacol Ther 1989; 46:264-271.
- Kleinman KS, Schweitzer S, & Nissenson AR: Accidental salicylate intoxication in a hemodialysis patient. Arch Intern Med 1988; 148:2277-2278.
- Krause DS, Wolf BA, & Shaw LM: Acute aspirin overdose: mechanisms of toxicity. Ther Drug Monit 1992; 14:441-451.
- Kraut JA & Madias NE: Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol 2010; 6(5):274-285.
- Kwong TC, Laczin J, & Baum J: Self-poisoning with enteric-coated aspirin. Am J Clin Pathol 1983; 80:888-890.
- LaCrosse-Rainfair: Safety Products, LaCrosse-Rainfair, Racine, WI, 1997.
- Lang B & Duffy CM: Controversies in the management of Kawasaki disease. Best Pract Res Clin Rheumatol 2002; 16(3):427-442.
- Leatherman JW & Schmitz PG: Fever, hyperdynamic shock, and multiple-system organ failure: a pseudo-sepsis syndrome associated with chronic salicylate intoxication. Chest 1991; 100:1391-1396.
- Legallicier B, Parent B, & Chamoun S: Toxicite rectale des suppositoires de Veganine(R): un mode de revelation original. Gastroenterol Clin Biol 1991; 15:92-93.
- Leonards JR: The influence of solubility on the rate of gastrointestinal absorption of aspirin. Clin Pharmacol Ther 1963; 4:476-479.
- Leventhal LJ, Kuritsky L, & Ginsburg R: Salicylate-induced rhabdomyolysis. Am J Emerg Med 1989; 7:409-410.
- Levy G & Leonards JR: Urine pH and salicylate therapy. JAMA 1971; 217:81.
- Levy G: Aspirin and bismuth subsalicylate (letter). Am J Dis Child 1993; 147:1281.
- Levy G: Clinical pharmacokinetics of aspirin. Pediatrics 1978; 62(Suppl 5):867-872.
- Levy RI: Overwhelming salicylate intoxication in an adult. Arch Intern Med 1967; 119:399-402.
- Lewis TV, Badillo R, Schaeffer S, et al: Salicylate toxicity associated with administration of percy medicine in an infant. Pharmacotherapy 2006; 26(3):403-409.
- Li JS, Yow E, Berezny KY, et al: Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference?. Circulation 2007; 116(3):293-297.
- Li JS, Yow E, Berezny KY, et al: Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial. Circulation 2008; 117(4):553-559.
- Liebman RM & Katz HM: Pulmonary edema in a 52-year-old woman ingesting large amounts of aspirin. JAMA 1981; 246:2227-2228.
- Litalien C & Jacqz-Aigrain E: Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. Paediatr Drugs 2001; 3(11):817-858.
- Loddenkemper T & Goodkin HP: Treatment of Pediatric Status Epilepticus. Curr Treat Options Neurol 2011; Epub:Epub.
- Lynd PA, Andreasen AC, & Wyatt RJ: Intrauterine salicylate intoxication in a newborn: A case report. Clin Pediatr 1976; 15:912.
- MAPA Professional: Chemical Resistance Guide. MAPA North America. Columbia, TN. 2003. Available from URL: http://www.mapaglove.com/pro/ChemicalSearch.asp. As accessed 4/21/2003.
- MAPA Professional: Chemical Resistance Guide. MAPA North America. Columbia, TN. 2004. Available from URL: http://www.mapaglove.com/ProductSearch.cfm?id=1. As accessed 6/10/2004.
- MacCready RA: Methyl salicylate poisoning: a report of five cases. N Engl J Med 1943; 228:155-156.
- Mackersie RC & Karagianes TG: Use of end-tidal carbon dioxide tension for monitoring induced hypocapnia in head-injured patients. Crit Care Med 1990; 18:764-765.
- Manikian A, Stone S, Hamilton R, et al: Exchange transfusion in severe infant salicylism. Vet Hum Toxicol 2002; 44(4):224-227.
- Manno EM: New management strategies in the treatment of status epilepticus. Mayo Clin Proc 2003; 78(4):508-518.
- Mar-Mac Manufacturing, Inc: Product Literature, Protective Apparel, Mar-Mac Manufacturing, Inc., McBee, SC, 1995.
- Marigold Industrial: US Chemical Resistance Chart, on-line version. Marigold Industrial. Norcross, GA. 2003. Available from URL: www.marigoldindustrial.com/charts/uschart/uschart.html. As accessed 4/14/2003.
- Mayer AL, Sitar DS, & Tenenbein M: Multiple-dose charcoal and whole-bowel irrigation do not increase clearance of absorbed salicylate. Arch Intern Med 1992; 152:393-396.
- McCleave DJ & Havill J: A review of acute salicylate poisoning. Anaesth Intens Care 1974; 4:340-344.
- McGuigan MA: A two-year review of salicylate deaths in Ontario. Arch Intern Med 1987; 147:510-512.
- McGuigan MA: Death due to salicylate poisoning in Ontario. Can Med Assoc J 1986; 135:891-894.
- Meghjee SPL & Wilson RJT: Acute anxiety - not always a psychiatrist's problem. Postgrad Med J 1998; 74(873):437-438.
- Meixensberger J, Baunach S, & Amschler J: Influence of body position on tissue-pO2, cerebral perfusion pressure and intracranial pressure in patients with acute brain injury. Neurol Res 1997; 19:249-253.
- Memphis Glove Company: Permeation Guide. Memphis Glove Company. Memphis, TN. 2001. Available from URL: http://www.memphisglove.com/permeation.html. As accessed 7/2/2001.
- Mitchell I: Therapeutic salicylate poisoning in children (letter). Br Med J 1979; 1081.
- Miyahara JT & Karler R: Effect of salicylate on oxidative phosphorylation and respiration of mitochondrial fragments. Biochem J 1965; 97:194-198.
- Monagle P, Chan AK, Goldenberg NA, et al: Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 suppl):e737S-e801S.
- Monagle P, Cochrane A, Roberts R, et al: A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. J Am Coll Cardiol 2011; 58(6):645-651.
- Mongan E, Kelly P, & Nies K: Tinnitus as an indication of therapeutic serum salicylate levels. JAMA 1973; 226:142-145.
- Montgomery H, Porter JC, & Bradley RD: Salicylate intoxication causing a severe systemic inflammatory response and rhabdomyolysis. Am J Emerg Med 1994; 12:531-532.
- Montgomery Safety Products: Montgomery Safety Products Chemical Resistant Glove Guide, Montgomery Safety Products, Canton, OH, 1995.
- Morgan AG & Polak A: Acetazolamide and sodium bicarbonate in treatment of salicylate poisoning in adults. Brit Med J 1969; 1:16-19.
- Morra P, Bartle WR, & Walker SE: Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother 1996; 30:935-940.
- Muizelaar JP, Marmarou A, Ward JD, et al: Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial.. J Neurosurg 1991; 75:731-739.
- Mukerji V, Alpert MA, & Flaker GC: Cardiac conduction abnormalities and atrial arrhythmias associated with salicylate toxicity. Pharmacotherapy 1986; 6:41-43.
- Mullick FG, Delage C, & Irey NS: Sickle cell crisis associated with drugs. Arch Environ Health 1973; 26:221-222.
- Musumba CO, Pamba AO, Sasi PA, et al: Salicylate poisoning in children: report of three cases. East Afr Med J 2004; 81(3):159-163.
- Myers EN & Bernstein JM: Salicylate ototoxicity: a clinical and experimental study. Arch Otolaryng 1965; 82:483-493.
- NFPA: Fire Protection Guide to Hazardous Materials, 13th ed., National Fire Protection Association, Quincy, MA, 2002.
- NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 1, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2001.
- NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 2, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2002.
- NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 3, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2003.
- NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 4, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2004.
- Nair J & Stacy M: Asceptic meningitis associated with salicylate overdose (letter). Psychosomatics 1993; 34:372.
- Naradzay J & Barish RA: Approach to ophthalmologic emergencies. Med Clin North Am 2006; 90(2):305-328.
- Nat-Wear: Protective Clothing, Hazards Chart. Nat-Wear. Miora, NY. 2001. Available from URL: http://www.natwear.com/hazchart1.htm. As accessed 7/12/2001.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2,3-Trimethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d68a&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2,4-Trimethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006m. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d68a&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2-Butylene Oxide (Proposed). United States Environmental Protection Agency. Washington, DC. 2008d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648083cdbb&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2-Dibromoethane (Proposed). United States Environmental Protection Agency. Washington, DC. 2007g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064802796db&disposition=attachment&contentType=pdf. As accessed 2010-08-18.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,3,5-Trimethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d68a&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 2-Ethylhexyl Chloroformate (Proposed). United States Environmental Protection Agency. Washington, DC. 2007b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648037904e&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Acrylonitrile (Proposed). United States Environmental Protection Agency. Washington, DC. 2007c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648028e6a3&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Adamsite (Proposed). United States Environmental Protection Agency. Washington, DC. 2007h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Agent BZ (3-quinuclidinyl benzilate) (Proposed). United States Environmental Protection Agency. Washington, DC. 2007f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803ad507&disposition=attachment&contentType=pdf. As accessed 2010-08-18.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Allyl Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2008. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648039d9ee&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Aluminum Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Arsenic Trioxide (Proposed). United States Environmental Protection Agency. Washington, DC. 2007m. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480220305&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Automotive Gasoline Unleaded (Proposed). United States Environmental Protection Agency. Washington, DC. 2009a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cc17&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Biphenyl (Proposed). United States Environmental Protection Agency. Washington, DC. 2005j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064801ea1b7&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Bis-Chloromethyl Ether (BCME) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006n. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648022db11&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Boron Tribromide (Proposed). United States Environmental Protection Agency. Washington, DC. 2008a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803ae1d3&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Bromine Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2007d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648039732a&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Bromoacetone (Proposed). United States Environmental Protection Agency. Washington, DC. 2008e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809187bf&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Calcium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Carbonyl Fluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2008b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803ae328&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Carbonyl Sulfide (Proposed). United States Environmental Protection Agency. Washington, DC. 2007e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648037ff26&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Chlorobenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2008c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803a52bb&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Cyanogen (Proposed). United States Environmental Protection Agency. Washington, DC. 2008f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809187fe&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Dimethyl Phosphite (Proposed). United States Environmental Protection Agency. Washington, DC. 2009. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cbf3&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Diphenylchloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethyl Isocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648091884e&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethyl Phosphorodichloridate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480920347&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2008g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809203e7&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethyldichloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Germane (Proposed). United States Environmental Protection Agency. Washington, DC. 2008j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963906&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Hexafluoropropylene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064801ea1f5&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ketene (Proposed). United States Environmental Protection Agency. Washington, DC. 2007. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ee7c&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Magnesium Aluminum Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Magnesium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Malathion (Proposed). United States Environmental Protection Agency. Washington, DC. 2009k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809639df&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Mercury Vapor (Proposed). United States Environmental Protection Agency. Washington, DC. 2009b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a8a087&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyl Isothiocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963a03&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyl Parathion (Proposed). United States Environmental Protection Agency. Washington, DC. 2008l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963a57&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyl tertiary-butyl ether (Proposed). United States Environmental Protection Agency. Washington, DC. 2007a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064802a4985&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methylchlorosilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2005. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5f4&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyldichloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyldichlorosilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2005a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c646&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Mustard (HN1 CAS Reg. No. 538-07-8) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6cb&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Mustard (HN2 CAS Reg. No. 51-75-2) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6cb&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Mustard (HN3 CAS Reg. No. 555-77-1) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6cb&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Tetroxide (Proposed). United States Environmental Protection Agency. Washington, DC. 2008n. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648091855b&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Trifluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2009l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963e0c&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Parathion (Proposed). United States Environmental Protection Agency. Washington, DC. 2008o. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963e32&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Perchloryl Fluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2009c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e268&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Perfluoroisobutylene (Proposed). United States Environmental Protection Agency. Washington, DC. 2009d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e26a&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phenyl Isocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008p. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096dd58&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phenyl Mercaptan (Proposed). United States Environmental Protection Agency. Washington, DC. 2006d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020cc0c&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phenyldichloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phorate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008q. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096dcc8&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phosgene (Draft-Revised). United States Environmental Protection Agency. Washington, DC. 2009e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a8a08a&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phosgene Oxime (Proposed). United States Environmental Protection Agency. Washington, DC. 2009f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e26d&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Potassium Cyanide (Proposed). United States Environmental Protection Agency. Washington, DC. 2009g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cbb9&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Potassium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Propargyl Alcohol (Proposed). United States Environmental Protection Agency. Washington, DC. 2006e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ec91&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Selenium Hexafluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2006f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ec55&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Silane (Proposed). United States Environmental Protection Agency. Washington, DC. 2006g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d523&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Sodium Cyanide (Proposed). United States Environmental Protection Agency. Washington, DC. 2009h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cbb9&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Sodium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Strontium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Sulfuryl Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2006h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ec7a&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tear Gas (Proposed). United States Environmental Protection Agency. Washington, DC. 2008s. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096e551&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tellurium Hexafluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2009i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e2a1&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tert-Octyl Mercaptan (Proposed). United States Environmental Protection Agency. Washington, DC. 2008r. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096e5c7&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tetramethoxysilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2006j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d632&disposition=attachment&contentType=pdf. As accessed 2010-08-17.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Trimethoxysilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2006i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d632&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Trimethyl Phosphite (Proposed). United States Environmental Protection Agency. Washington, DC. 2009j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7d608&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Trimethylacetyl Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2008t. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096e5cc&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Zinc Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for n-Butyl Isocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008m. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064808f9591&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
- National Institute for Occupational Safety and Health: NIOSH Pocket Guide to Chemical Hazards, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Cincinnati, OH, 2007.
- National Research Council : Acute exposure guideline levels for selected airborne chemicals, 5, National Academies Press, Washington, DC, 2007.
- National Research Council: Acute exposure guideline levels for selected airborne chemicals, 6, National Academies Press, Washington, DC, 2008.
- National Research Council: Acute exposure guideline levels for selected airborne chemicals, 7, National Academies Press, Washington, DC, 2009.
- National Research Council: Acute exposure guideline levels for selected airborne chemicals, 8, National Academies Press, Washington, DC, 2010.
- Neese Industries, Inc.: Fabric Properties Rating Chart. Neese Industries, Inc.. Gonzales, LA. 2003. Available from URL: http://www.neeseind.com/new/TechGroup.asp?Group=Fabric+Properties&Family=Technical. As accessed 4/15/2003.
- Newburger JW, Takahashi M, Gerber MA, et al: Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association . Circulation 2004; 110(17):2747-2771.
- Ng J & Ganesan V: Expert opinion on emerging drugs in childhood arterial ischemic stroke. Expert Opin Emerg Drugs 2011; 16(2):363-372.
- Niehoff JM & Baltazis PA: Adult respiratory distress syndrome induced by salicylate toxicity. Postgrad 1985; 78:117-123.
- None Listed: Position paper: cathartics. J Toxicol Clin Toxicol 2004; 42(3):243-253.
- None Listed: The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Hyperventilation. J Neurotrauma 2000a; 17(6-7):513-520.
- None Listed: The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Use of mannitol. J Neurotrauma 2000; 17(6-7):521-525.
- Norgard B, Puho E, Czeizel AE, et al: Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol 2005; 192(3):922-923.
- North: Chemical Resistance Comparison Chart - Protective Footwear . North Safety. Cranston, RI. 2002. Available from URL: http://www.linkpath.com/index2gisufrm.php?t=N-USA1. As accessed April 30, 2004.
- North: eZ Guide Interactive Software. North Safety. Cranston, RI. 2002a. Available from URL: http://www.northsafety.com/feature1.htm. As accessed 8/31/2002.
- Nowak JJ, Brundhofer B, & Gibaldi M: Rectal absorption from aspirin suppositories in children and adults. Pediatrics 1974; 54:23.
- O'Brien WM: Trolamine salicylate cream in osteoarthritis. JAMA 1982; 248:1577.
- O'Gorman T & Koff RF: Salicylate hepatitis. Gastroenterol 1977; 72:726-728.
- Palatnick W & Tenenbein M: Aspirin poisoning during pregnancy: increased fetal sensitivity. Am J Perinatol 1998; 15:39-41.
- Patel DK, Hesse A, & Ogunbona A: Metabolism of aspirin after therapeutic and toxic doses. Human Exper Toxicol 1990; 9:131-136.
- Paul BN: Salicylate poisoning in the elderly: diagnostic pitfalls. J Am Geriatr Soc 1972; 20:387-390.
- Payntes AS & Alexander FW: Salicylate intoxication caused by teething ointment (letter). Lancet 1979; 1132.
- Peate WF: Work-related eye injuries and illnesses. Am Fam Physician 2007; 75(7):1017-1022.
- Pec J, Strmenova M, & Palencarova E: Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis 1992; 50:307-309.
- Pei YPC & Thompson DA: Severe salicylate intoxication mimicking septic shock (letter). Am J Med 1987; 82:381-382.
- Pena-Alonso YR, Montoya-Cabrera MA, Bustos-Cordoba E, et al: Aspirin intoxication in a child associated with myocardial necrosis: is this a drug-related lesion?. Ped Develop Pathol 2003; 6:342-347.
- Personal Communication: Personal Communication: Frank S Akin, Ph D, Director Pharmacology and Toxicology. Plough Inc, Memphis, Tennessee, 1981.
- Personal Communication: Personal Communication: Helen Lester, LPN. Personal Communication, 1984.
- Pickering D: Salicylate poisoning as a manifestation of the battered child syndrome. Am J Dis Child 1976; 130:675-676.
- Pierce RP, Gazewood J, & Blake RL Jr: Salicylate poisoning from enteric-coated aspirin: delayed absorption may complicate management. Postgrad Med 1991; 89:61-64.
- Pinsky PF, Hurwitz ES, & Schonberger LB: Reye's syndrome and aspirin: evidence for a dose-response effect. JAMA 1988; 260:657-661.
- Playtex: Fits Tough Jobs Like a Glove, Playtex, Westport, CT, 1995.
- Polin RS, Shaffrey ME, & Bogaev CA: Decompressive bifrontal craniectomy in the treatment of severe refractory posttraumatic cerebral edema. Neurosurgery 1997; 41:84-92.
- Pollack MM, Dunbar BS, & Holbrook PR: Aspiration of activated charcoal and gastric contents. Ann Emerg Med 1981; 10:528-529.
- Pond SM, Armstong JG, & Henderson A: Late diagnosis of chronic salicylate intoxication (letter). Lancet 1993; 342:687.
- Posner JB & Plum F: Spinal fluid pH and neurological symptoms in systemic acidosis. N Engl J Med 1967; 227:605-613.
- Prescott LF, Balali-Mood M, & Critchley JAJH: Diuresis or urinary alkalinization for salicylate poisoning?. Br Med J 1982; 285:1383-1386.
- Product Information: AGGRENOX(R) oral capsules, aspirin/extended-release dipyridamole oral capsules. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, 2009.
- Product Information: BUFFERIN(R) extra-strength oral tablets, aspirin extra-strength oral tablets. Novartis Consumer Health,Inc, Parsippany, NJ, 2007.
- Product Information: BUFFERIN(R) oral tablets, aspirin oral tablets. Novartis Consumer Health,Inc, Parsippany, NJ, 2007.
- Product Information: DURLAZA(TM) oral extended release capsules, aspirin oral extended release capsules. New Haven Pharmaceuticals (per manufacturer), North Haven, CT, 2015.
- Product Information: Fiorinal(R) oral capsules, Butalbital, Aspirin, and Caffeine oral capsules. Watson Pharmaceuticals, Inc., Corona, CA, 2007.
- Product Information: HELIDAC(R) Therapy oral chewable tablets, tablets, capsules, bismuth subsalicylate, metronidazole, tetracycline hydrochloride oral chewable tablets, tablets, capsules. Prometheus Laboratories, San Diego, CA, 2007.
- Product Information: PASER(R) delayed-release granules, aminosalicylic acid delayed-release granules. Jacobus Pharmaceutical Company,Inc, Princeton, NJ, 1996.
- Product Information: Pepto-Bismol Original Liquid, Maximum Strength Liquid, Original and Cherry Tablets and Easy-to-Swallow Caplets, Bismuth subsalicylate. Procter and Gamble, Cincinnati, OH, 2004.
- Product Information: SOMA(R) COMPOUND oral tablets, carisoprodol aspirin oral tablets. Meda Pharmaceuticals Inc. (per FDA), Somerset, NJ, 2013.
- Product Information: SOMA(R) COMPOUND with CODEINE oral tablets, carisoprodol aspirin codeine phosphate oral tablets. Meda Pharmaceuticals Inc. (per FDA), Somerset, NJ, 2013.
- Product Information: SOMA(R) COMPOUND with CODEINE oral tablets, carisoprodol aspirin codeine phosphate oral tablets. Meda Pharmaceuticals Inc. (per FDA), Somerset, NJ, 2013a.
- Product Information: VITAMIN K1 injection, phytonadione injection. Hospira,Inc, Lake Forest, IL, 2004.
- Product Information: choline magnesium trisalicylate oral tablets, choline magnesium trisalicylate oral tablets. Caraco Pharmaceutical Laboratories,LTD, Detroit, MI, 1999.
- Product Information: diazepam IM, IV injection, diazepam IM, IV injection. Hospira, Inc (per Manufacturer), Lake Forest, IL, 2008.
- Product Information: lorazepam IM, IV injection, lorazepam IM, IV injection. Akorn, Inc, Lake Forest, IL, 2008.
- Proudfoot AT & Brown SS: Acidemia and salicylate poisoning in adults. Br Med J 1969; 2:547-550.
- Prowse K, Pain M, & Marston AD: The treatment of salicylate poisoning using mannitol and forced alkaline diuresis. Clin Sci 1970; 38:327-337.
- Quail MT: Non-aspirin salicylates (NAS). Clin Tox Review by Massachusetts Poison Control System, 16 (No. 12), 1994.
- Quint PA & Allman FD: Differentiation of chronic salicylism from Reye syndrome. Pediatrics 1984; 74:1117-1119.
- Ralston ME, Pearigan PD, & Ponaman ML: Transient myocardial dysfunction in a child with salicylate toxicity. J Emerg Med 1995; 13:657-659.
- Ramsden RT, Latif A, & O'Malley S: Electrocochleographic changes in acute salicylate overdosage. J Laryngol Otol 1985; 99:1269-1273.
- Raschke R, Arnold-Capell PA, & Richeson R: Refractory hypoglycemia secondary to topical salicylate intoxication. Arch Intern Med 1991; 151:591-593.
- Rau NR, Nagaraj MV, Prakash PS, et al: Fatal pulmonary aspiration of oral activated charcoal. Br Med J 1988; 297:918-919.
- Rauschka H, Aboul-Enein F, Bauer J, et al: Acute cerebral white matter damage in lethal salicylate intoxication. Neurotoxicology 2007; 28(1):33-37.
- Reid IR: Transient hypercalcemia following overdoses of soluble aspirin tablets (letter). Aust NZ J Med 1985; 15:364.
- Rejent TA & Baik S: Fatal in utero salicylism. J Forensic Sci 1985; 30:942-944.
- Rich RR & Johnson JS: Salicylate hepatotoxicity in patients with juvenile rheumatoid arthritis. Arthritis Rheum 1973; 16:1-9.
- River City: Protective Wear Product Literature, River City, Memphis, TN, 1995.
- Rivera W, Kleinschmidt KC, Velez LI, et al: Delayed salicylate toxicity at 35 hours without early manifestations following a single salicylate ingestion. Ann Pharmacother 2004; 38:1186-1188.
- Roach ES, Golomb MR, Adams R, et al: Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39(9):2644-2691.
- Robin ED, Davis RP, & Rees SB: Salicylate intoxication with special reference to the development of hypokalemia. Am J Med 1959; 26869-882.
- Robins JB, Turnbull JA, & Robertson C: Gastric perforation after acute aspirin overdose. Human Toxicol 1985; 4:527-528.
- Rodin MB, Semla TP, & Svanborg A: Salicylate intoxication presenting with "pseudoexacerbation" of a focal neurologic deficit. Am Geriatr Soc 1991; 39:400-402.
- Rosenfeld RG & Liebhaber MI: Acute encephalopathy in siblings. Am J Dis Child 1976; 130:295-297.
- Rowley AH & Shulman ST: Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 2010; 8(2):197-203.
- Rumack CM, Guggenheim MA, Rumack BH, et al: Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet Gynecol 1981; 58(suppl):52-56.
- Rupp DJ, Seaton RD, & Wiegmann TB: Acute polyuric renal failure after aspirin intoxication. Arch Intern Med 1983; 143:1237-1238.
- Ruscin JM & Astroth JD: Lingual lesions secondary to prolonged contact with salsalate tablets. Ann Pharmacother 1998; 32:1248.
- Ruskosky D, Schauben J, & Kunisaki T: Urinary alkalinization compared to multidose activated charcoal for the enhancement of salicylate elimination (abstract). J Tox Clin Tox 1998; 36:446.
- Sacchetti A & Ramoska E: Ingestion of compound W(R), an unusual caustic. Am J Emerg Med 1986; 4:554-555.
- Safety 4: North Safety Products: Chemical Protection Guide. North Safety. Cranston, RI. 2002. Available from URL: http://www.safety4.com/guide/set_guide.htm. As accessed 8/14/2002.
- Sahuquillo J & Arikan F: Decompressive craniectomy for the treatment of refractory high intracranial pressure in traumatic brain injury. Cochrane Database Syst Rev 2006; 2006(1):CD003983-.
- Sainsbury SJ: Fatal salicylate toxicity from bismuth salicylate. West J Med 1991; 155:637-639.
- Sakai K, Iwahashi K, & Terada K: Outcome after external decompression for massive cerebral infarction. Neurol Med Chir 1998; 38:131-136.
- Schlegel RJ, Altstatt LB, & Canales L: Peritoneal dialysis for severe salicylism: an evaluation of indications and results. J Pediatr 1966; 69:553-562.
- Schneider GH, von Helden GH, & Franke R: Influence of body position on jugular venous oxygen saturation, intracranial pressure and cerebral perfusion pressure. Acta Neurochir 1993; 59(suppl):107-112.
- Schwartz R & Landy G: Organic acid excretion in salicylate intoxication. J Pediatr 1965; 66:658-666.
- Scott R, Besag FMC, & Neville BGR: Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomized trial. Lancet 1999; 353:623-626.
- Segar WE: The critically ill child: salicylate intoxication. Pediatrics 1969; 44:440-444.
- Servus: Norcross Safety Products, Servus Rubber, Servus, Rock Island, IL, 1995.
- Shahidi NT & Westring DW: Acetylsalicylic acid - induced hemolysis and its mechanism. J Clin Investig 1970; 49:1334-1340.
- Shelley WB: Birch pollen and aspirin psoriasis. JAMA 1964; 189:985-988.
- Shkrum MJ, Gay RM, & Hudson P: Fatal iatrogenic salicylate intoxication in a long-term user of enteric-coated aspirin. Arch Pahol Lab med 1989; 113:89-90.
- Sienko DG, Anda RF, & McGee HB: Reye's syndrome and salicylates (letter). JAMA 1987; 258:3117-3119.
- Skjoto J & Reikvam A: Hyperthermia and rhabdomyolysis in self-poisoning with paracetamol and salicylates. Acta Med Scand 1979; 205:473-476.
- Smith MJH: The Salicylates, Wiley-Interscience, New York, NY, 1966, pp 39-43.
- Smith MJH: The metabolic basis of the major symptoms in acute salicylate intoxication. Clin Toxicol 1968; 1:387-407.
- Smith PK: The pharmacology of salicylates and related compounds. Ann Acad Sci 1960; 86:38-63.
- Smith SW, Ling LJ, & Halstenson CE: Whole-bowel irrigation as a treatment for acute lithium overdose. Ann Emerg Med 1991; 20:536-539.
- Snodgrass W, Rumack BH, & Peterson RG: Salicylate toxicity following therapeutic doses in young children. Clin Toxicol 1981; 18:247-259.
- Sogge MR, Griffith JL, & Sinar DR: Lavage to remove enteric-coated aspirin and gastric outlet obstruction. Ann Intern Med 1977; 87:721.
- Spiller HA & Rogers GC: Evaluation of administration of activated charcoal in the home. Pediatrics 2002; 108:E100.
- Springer DJ & Groll A: Poisoning with enteric-coated acetylsalicylic acid complicating gastric outlet obstruction. Can Med Assoc J 1980; 122:1032-1034.
- Sreenath TG, Gupta P, Sharma KK, et al: Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: A randomized controlled trial. Eur J Paediatr Neurol 2009; Epub:Epub.
- Standard Safety Equipment: Product Literature, Standard Safety Equipment, McHenry, IL, 1995.
- Starko KM & Mullick FG: Hepatic and cerebral pathology findings in children with fatal salicylate intoxication: further evidence for a causal relation between salicylate and Reye's syndrome. Lancet 1983; 1:326-329.
- Steele TE & Morton WA: Salicylate-induced delirium. Psychosomatics 1986; 27:455-456.
- Stolbach AI, Hoffman RS, & Nelson LS: Mechanical ventilation was associated with acidemia in a case series of salicylate-poisoned patients. Acad Emerg Med 2008; 15(9):866-869.
- Strater R, Kurnik K, Heller C, et al: Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. Stroke 2001; 32(11):2554-2558.
- Streissguth AP, Treder RP, & Barr HM: Aspirin and acetaminophen use by pregnant women and subsequent child IQ and attention decrements. Teratology 1987; 35:211-219.
- Stuart MJ, Gross SJ, & Elrad H: Effects of acetyl salicylic acid ingestion on maternal and neonatal hemostasis. N Engl J Med 1982; 307:909-912.
- Surapathana LA-OR, Futrakul P, & Campbell RA: Salicylism revisited: unusual problems in diagnosis and management. Clin Pediatr 1970; 9:658-661.
- Sweeney KR, Chapron DJ, & Brandt JL: Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin Pharmacol Ther 1986; 40:518-524.
- Tam LS, Chan TYK, & Leung WK: Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil (letter). Aust NZ J Med 1995; 25:258.
- Tashima CK & Rose M: Pulmonary edema and salicylates (letter). Ann Intern Med 1974; 81:274-275.
- Taylor A, Butt W, & Rosenfeld J: A randomized trial of very early decompressive craniectomy in children with traumatic brain injury and sustained intracranial hypertension. Childs Nerv Syst 2001; 17:154-162.
- Temple AR, George DJ, & Done AK: Salicylate poisoning complicated by fluid retention. Clin Toxicol 1976; 9:61-68.
- Temple AR: Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med 1981; 141:364-369.
- Tenenbein M, Cohen S, & Sitar DS: Whole bowel irrigation as a decontamination procedure after acute drug overdose. Arch Int Med 1987; 147:905-907.
- Thakore S & Murphy N: The potential role of prehospital administration of activated charcoal. Emerg Med J 2002; 19:63-65.
- Thisted B, Krantz T, & Strom J: Acute salicylate self-poisoning in 177 consecutive patients treated in ICU. Acta Anaesthesiol Scand 1987; 31(4):312-316.
- Thomas C: Adult respiratory-distress syndrome in salicylate intoxication (letter). Lancet 1979; 2:1294-1295.
- Thun MJ: Aspirin, NSAIDS, and digestive tract cancers. Cancer & Metastasis Rev 1994; 13:269-277.
- Thurston JH, Pollock PG, & Warren SK: Reduced brain glucose with normal plasma glucose in salicylate poisoning. J Clin Invest 1970; 49:2139-2145.
- Tingley: Chemical Degradation for Footwear and Clothing. Tingley. South Plainfield, NJ. 2002. Available from URL: http://www.tingleyrubber.com/tingley/Guide_ChemDeg.pdf. As accessed 10/16/2002.
- Todd PJ, Sills JA, & Harris F: Problems with overdoses of sustained-release aspirin (letter). Lancet 1981; 777.
- Trelleborg-Viking, Inc.: Chemical and Biological Tests (database). Trelleborg-Viking, Inc.. Portsmouth, NH. 2002. Available from URL: http://www.trelleborg.com/protective/. As accessed 10/18/2002.
- Trelleborg-Viking, Inc.: Trellchem Chemical Protective Suits, Interactive manual & Chemical Database. Trelleborg-Viking, Inc.. Portsmouth, NH. 2001.
- Tsimihodimos V, Psychogios N, Kakaidi V, et al: Salicylate-induced proximal tubular dysfunction. Am J Kidney Dis 2007; 50(3):463-467.
- Tuckler V, Connolly SE, & Martinez J: Hypertriglyceridemia causing a falsely positive toxic serum salicylate level (abstract). J Toxicol - Clin Toxicol 2001; 39:484.
- U.S. Department of Energy, Office of Emergency Management: Protective Action Criteria (PAC) with AEGLs, ERPGs, & TEELs: Rev. 26 for chemicals of concern. U.S. Department of Energy, Office of Emergency Management. Washington, DC. 2010. Available from URL: http://www.hss.doe.gov/HealthSafety/WSHP/Chem_Safety/teel.html. As accessed 2011-06-27.
- U.S. Department of Health and Human Services, Public Health Service, National Toxicology Project : 11th Report on Carcinogens. U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. Washington, DC. 2005. Available from URL: http://ntp.niehs.nih.gov/INDEXA5E1.HTM?objectid=32BA9724-F1F6-975E-7FCE50709CB4C932. As accessed 2011-06-27.
- U.S. Environmental Protection Agency: Discarded commercial chemical products, off-specification species, container residues, and spill residues thereof. Environmental Protection Agency's (EPA) Resource Conservation and Recovery Act (RCRA); List of hazardous substances and reportable quantities 2010b; 40CFR(261.33, e-f):77-.
- U.S. Environmental Protection Agency: Integrated Risk Information System (IRIS). U.S. Environmental Protection Agency. Washington, DC. 2011. Available from URL: http://cfpub.epa.gov/ncea/iris/index.cfm?fuseaction=iris.showSubstanceList&list_type=date. As accessed 2011-06-21.
- U.S. Environmental Protection Agency: List of Radionuclides. U.S. Environmental Protection Agency. Washington, DC. 2010a. Available from URL: http://www.gpo.gov/fdsys/pkg/CFR-2010-title40-vol27/pdf/CFR-2010-title40-vol27-sec302-4.pdf. As accessed 2011-06-17.
- U.S. Environmental Protection Agency: List of hazardous substances and reportable quantities. U.S. Environmental Protection Agency. Washington, DC. 2010. Available from URL: http://www.gpo.gov/fdsys/pkg/CFR-2010-title40-vol27/pdf/CFR-2010-title40-vol27-sec302-4.pdf. As accessed 2011-06-17.
- U.S. Environmental Protection Agency: The list of extremely hazardous substances and their threshold planning quantities (CAS Number Order). U.S. Environmental Protection Agency. Washington, DC. 2010c. Available from URL: http://www.gpo.gov/fdsys/pkg/CFR-2010-title40-vol27/pdf/CFR-2010-title40-vol27-part355.pdf. As accessed 2011-06-17.
- U.S. Occupational Safety and Health Administration: Part 1910 - Occupational safety and health standards (continued) Occupational Safety, and Health Administration's (OSHA) list of highly hazardous chemicals, toxics and reactives. Subpart Z - toxic and hazardous substances. CFR 2010 2010; Vol6(SEC1910):7-.
- U.S. Occupational Safety, and Health Administration (OSHA): Process safety management of highly hazardous chemicals. 29 CFR 2010 2010; 29(1910.119):348-.
- Ulshen MH, Grand RJ, & Crain JD: Hepatotoxicity with encephalopathy associated with aspirin therapy in rheumatoid arthritis. J Pediatr 1978; 93:1034-1037.
- United States Environmental Protection Agency Office of Pollution Prevention and Toxics: Acute Exposure Guideline Levels (AEGLs) for Vinyl Acetate (Proposed). United States Environmental Protection Agency. Washington, DC. 2006. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6af&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
- Vale JA, Kulig K, American Academy of Clinical Toxicology, et al: Position paper: Gastric lavage. J Toxicol Clin Toxicol 2004; 42:933-943.
- Vale JA: Position Statement: gastric lavage. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997; 35:711-719.
- Vandenberg SA, Smolinske SC, & Spoerke DG: Non-aspirin salicylates: conversion factors for estimating aspirin equivalency. Vet Hum Toxicol 1989; 31:49-50.
- Varela N, Bognar M, & Agudelo C: Salicylate toxicity in the older patient. J Clin Rheumatol 1998; 4:1-5.
- Vazquez Martinez JL, Stanescu S, Castrillo Bustamante S, et al: Unrecognized transcutaneous severe salicylate intoxication in an infant. Pediatr Emerg Care 2015; 31(9):e8.
- Velez LI, Keyes DC, & Roth B: Aspirin overdose in mother and fetus (abstract). J Toxicol - Clin Toxicol 2001; 39:483-484.
- Vermeersch G, Marko J, & Cartigny B: Salicylate poisoning detected by (1)H NMR spectroscopy (letter). Clin Chem 1988; 34:1003-1004.
- Vertrees JE, McWilliams BC, & Kelly HW: Repeated oral administration of activated charcoal for treating aspirin overdose in young children. Pediatrics 1990; 85:594-598.
- Waldman RJ, Hall WN, & McGee H: Aspirin as a risk factor in Reye's syndrome. JAMA 1982; 247:3089-3094.
- Walters JS, Woodring JH, & Stelling CB: Salicylate-induced pulmonary edema. Radiology 1983; 146:289-293.
- Watson JE & Tagupa ET: Suicide attempt by means of aspirin enema. Ann Pharmacother 1994; 28:467-469.
- Weiner AL, Ko C, & McKay CA: A comparison of two bedside tests for the detection of salicylates in urine. Acad Emerg Med 2000; 7(7):834-836.
- Weiss HJ & Aledort LM: Impaired platelet/connective-tissue reaction in man after aspirin ingestion. Lancet 1967; 2:495-497.
- Wells Lamont Industrial: Chemical Resistant Glove Application Chart. Wells Lamont Industrial. Morton Grove, IL. 2002. Available from URL: http://www.wellslamontindustry.com. As accessed 10/31/2002.
- Whitehall J: Fatal salicylate poisoning: report on three fatal cases. J Med 1973; 19:25-26.
- Widdop B, Medd RK, & Braithwaite RA: Experimental drug intoxication: treatment with charcoal haemoperfusion. Arch Toxicol 1975; 34:27-36.
- Winchester JF, Gelfand MC, & Helliwell M: Extracorporeal treatment of salicylate or acetaminophen poisoning - is there a role?. Arch Intern Med 1981; 141:370-374.
- Wise CM, Owen DS, & Jessee EF Jr: Another case of salicylate intoxication with enteric coated aspirin association with gastric outlet obstruction (letter). J Rheumatol 1982; 9:482-483.
- Wolowich WR, Hadley CM, Kelley MT, et al: Plasma salicylate from methyl salicylate cream compared to oil of wintergreen. J Toxicol Clin Toxicol 2003; 41:355-358.
- Wong KS, Mok V, & Lam WWM: Aspirin-associated intracerebral hemorrhage. Clinical and radiologic features. Neurol 2000; 54:2298-2301.
- Workrite: Chemical Splash Protection Garments, Technical Data and Application Guide, W.L. Gore Material Chemical Resistance Guide, Workrite, Oxnard, CA, 1997.
- Wortzman DJ & Grunfeld A: Delayed absorption following enteric-coated aspirin overdose. Ann Emerg Med 1987; 16:434-436.
- Yamamura S, Kinoshita Y, Kitamura N, et al: Neonatal salicylate poisoning during the treatment of a collodion baby. Clin Pediatr (Phila) 2002; 41(6):451-452.
- Yeakel D, Stemple C, & Dougherty J: A prospective human crossover study on single versus multiple dose charcoal in salicylate ingestion (abstract). Ann Emerg Med 1988; 17:439.
- Yeary RA & Swanson W: Aspirin dosages for the cat. JAVMA 1973; 163:1177-1178.
- Zimmer BW, Marcus RJ, Sawyer K, et al: Salicylate intoxication as a cause of pseudohyperchloremia. Am J Kidney Dis 2008; 51(2):346-347.
- Zimmerman GA & Clemmer TP: Acute respiratory failure during therapy for salicylate intoxication. Ann Emerg Med 1981; 10:104-106.
- Zucker P, Daum F, & Cohen MI: Aspirin Hepatitis. Am J Dis Child 1975; 129:1433-1434.
|